var title_f17_3_17456="PDR neovascularization disc";
var content_f17_3_17456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proliferative diabetic retinopathy displaying prominent neovascularization at the disc (NVD): Appearance on fundus photograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color fundus photograph of proliferative diabetic retinopathy displaying prominent neovascularization at the disc (NVD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17456=[""].join("\n");
var outline_f17_3_17456=null;
var title_f17_3_17457="Chest radiograph with rupture of the left hemidiaphragm";
var content_f17_3_17457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79270&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Chest radiograph with rupture of the left hemidiaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 434px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGyAcUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5ant5IWKupGD1xUNey3GjWMoIktEIJ6AYrLvPBen3KN9nVon7EHp+FAHl1FdXfeC763JMbrKvqBWXJ4fvUHKZPpg0AZFOCkjjn6Vak0+6jPzQv/3yaakbrIPlIINAFYgjqCKStqOOOUYmjBY9wMGibRSebdwfY0AYtFT3NrLbsRKhHvjioaAErXsdCubuJZFwEYZBxmo9F06a+n2JBI4PG4A4H41614Q0GaCzWO42gLwAeooA8yu/DF1BbGVSXI/hC1lNbnygQrBxwykc19HLodsy4YAg9a5jxJYafpUbTw2SFwOSFoA8UjtZ5GwkMhPsprUt/D1zKgaRhH7EZNXNY1yZLlhBCkQ9+SazDqWoXGQ1w4B9OP5UAXhodrF/x8Xf4DArU09tHt1Cp5cjD/gRNcdKJN/7wlie5OavaZGwbcpGTxQB2Y1WGPiG2A98Ypw1iduFjQfnWYkRIzmp44zmgC39tuXz+8I9hQHkY/M7Z+tNSM7eMVKqjPvQA0jmpIMqc9vSn7M9qcFAxwaALHBA6Cq10uSpBPB7GpkByAB+NJPEcdRmgCvcSjgMO3XmrFhKiugDHGGH61DcQFkUHHSixtCjDc4yrH9aALcUiM5+YmpGkTyJDnHIqraxIsjhjVnZEluwGDlhxQBSctcMDzsFQsh3kKCTnGK1YLGaUgqPLT3qeZbewAJVZJT09aAKFrpjuN0rFB6CnX95b6dEwhVXlx0z3qrf6hO54JjHoP8AGsWUnkt1PWgClqmoXF05818Kf4AeBWNOvzHAFad0oLdBUDxDbuIoAy5BtGDUFW51y1VmGDQA2iir+m6ZNfNlBtjB5Y0AVrW3e5lCRjPqfSrk+yw+SPDy92ParN/cRaehtbMDzBw8nBrFJLMSSST1JoAV2Zzljk02lrTsbFVgN1djEQGVX1oArW1ruUyzZWJf1qO4mMpwBtQcACn3121ywAGyMfdQdBVWgAop8UbSOFQEseMCul0vw+Aolu8N/s9qAMK0sJ7o/u0IX1Nb+laJClzF5x8xiemOBWtsEUe23jA2j0q74fsJDPLcTH+HAHpQBkeLJ2+0JBHwqDJxWFDazXDFcHbnuK6jVmsbad5rkCRieBnNc5f6vNNlbRPIj6AjqaAHT21rbRgTSAuB0wM1Te/ij4iiDH1aqUiOWy5JY9c96u6dpU11KNylE9SKAKUs8k79APZRXW/DpJLHxLZTM2Fl+Qj61LbaLBBHnYpbrk1o6dCsN3BKq8o6sPwNAHuNsMR0VYtAGhVl6EAiigDzVoCQTjPXOKqyRkIcA5+tdNeWTwRk1mTxFgOCTjtQBgu7Z2sWzVW4h80cO4P1rZubJ5DlYyT9KqvYyIuWQ5zQByt3carZSZASe37grk4qW2v9HvtqXkQinPByCozW+1nK5KrEzZ9BUE3hUXQ3SqIie460AZl14eCEva4dOvXmqcFhcGTYkTFs11dnBb6DFtmuWmQdm5xV+HVLO5UCAAe/SgDn7XQGuItt4oCkdM1WutF0jRlM/lfdHOSWNbt4Ji5IY7OwWgWiXMO1wC2O4oA5u18QJ5oSwjwp7lcV2Phu7ubm4xK+cgHA4rj7zRmsLxWjQ+UxzwOldXoCmKWFh64NAHolpANnANYXi3TxPYzIF+YqcV1WnEMo4HSjVbMTWzDHagD5m8RadsUnad65zWXp8LSIrYr1DxLozedOFGeT2rjLGzMTtE6kbSeooAxby12up6GrmmW59Otak9qrjJFMtYgrj2NAEyxgZHOetTxirBiDDOKSNCDyKABV4HWpkXnOKVRxyKkXqMCgBduep/OniPkcUzB9DU0Wc+1AE0cPApskBPNTKuarlmBIzigBtxHiNMfnTLNSZseoqxtZ4kHU1asrNllWSQhPb1oAzkt2a4KquSTWtFaxW0AaUfNnvUkk8cJKwrluhqtcB5Y1JJPPSgCOa8dyVi4Xp0qvJD8pZjzjvTwm0E45HeqrhmJyT1oApTxxkZBrOvUAfAHBHFa8kWRgCqF1EwHrigDIePPUcVWmYHgnj0rSuEkcYVeB3qhLbvySv0oAy7nCg+tUGGa0pRuY9MUlpYveXCxRLkk847CgBmjaa+oXYQA+UvLnOMCtvW9RSxi+xWeAwGDj+EVo3flaHpot7UqbgjqeM8cmuNlV3dmblicmgCqeTRV2OzO3c3U9BVzR9IOpXB3ErAn3mA/SgCPQ9ONy5nlA8hPXuai1i9+0z7EI8lOFx3962Nfn8uNNPsBlAMOVH6VkwaXIx/efLQBnKpZsDmpre2kuZljhUsx4+lb1norTOEiU7e7YrqtL0iDT4gcAueScc0AZ2jaKllCsjr+8x8xPNXnDSPgcr2FX2Rm/h+XNTRxJEu5gM0AQW1sEi3SjAHX6VNLcrFo8skBwCDg+vasnUrh7qTyo+F+7wavaynk6VBCBjoD+AoA42S3Luzvkk9zUYt9w2quSelbUFs0z7VX8a27DTo4xllBf1xQBzljpKqQ8yAnt7VtQRKjAhc10ENuuMEDH0qZdOgkwBwfYUAYghL4JFT21pwSRxmt9NIRcZerMOnRrkcn3oA7Xw3IJdHt3bJO3B/Cim+FFMemmIjOxzj6GigCnPKl5EfLC7Sehqg1sRgBFyfStKHT/ALOoMjgY4wKlDwIflwTQBjtZuxI2ge9MbTl24lZSPStC7nkDHYAB61mTsxBLMaAIbiWC3UiJQSOwFYd9cyy7vLbZ7VpyLweOapTR/NnFAHOzRhyQ/J75qvDD9llJX7p5xWxeRAP0qIQbx0oAtWrebEAe3ep4U2yZHBqKxj2Nsb8KutEVfJHA70ASS2sd1CysBn3qOytGtztPPoat2y5YetbEMaOgVx8w60AbmjsGjQ4wcVrSruiIxWLo4MZ2HkV0CAMPYigDzvxBGkd628ZDVx9/psTztNGVGe1eheMtPMgMiZyuTXBtCxcM2cUAZMtlmM7azmgKSHIPX0rrBGAMEZFVbi2Rm6HmgDLhUlRSSptPFXmtsfdFNMBbtQBTUGrUEeU3cc1KluB161MkZ24U9KAKzihanMJJyaVYCx+UZNACg8D1psMDTSHA4z1NX4bLHzTdPSo57oR/JCuO2aAJAkVpEC5Gazpr95plEWQmcYzVhwZosyc471VSFRMpTA5oAnQ77gjHSrKKSyZ6HNRlXWUkdO9EpbK4yCRQBWkO1mUt3qFkxz2NW0gBOW6mmTxs3yKOKAM9jk4qpOcZANXZojH161XkjBxgHPvQBnynjHrVZl3MVzWjJDuGCOaYLYBs96AOeurXbOyqo56DFdFpFgmmWbXMwHmMvPGKt6Xpqz3PnsPlTkfWoddkeZvKXhFPX1oA5q/d7udpnB+Y4APYVFHa5G5hwOgxWxFYsxI28VbXTW4ZxwO2aAMAWzzypDAp3v8AoK6SSAaTpyQQgeZjHHr61r6Vp0dlA08g+Yjv2qnLBJeXDPjrwKAOegshuLNgknca07TS2mbLjag5AxWza6ckLbpOWq03ogwPWgCCKGO3UBAo+lG3eQTUwjH1qUIAORxQBCqkDPaqGozlV8tSdxrQuHVEOOtZEiFn3Hk0AQ2MG68iHqwJNaevqXmiiHYZNP0O3L3e7HCjmrOpp/pbY7UAU7K2WOP7vP0q9HHyKWFf3YOODUyr6UAPi6cVdt1O4cc+tRW8JOKuxqicbhmgCyi5JNTwxFnB7VHbKTn0q/GAoFAF/TZvJWRRxkg8UVmSzMshC80UAWbmcyJ87/gKpJKsb8k1MRuBrPuAcnmgDV8yOSMAlgPWqlxGNuEIIpNPO5NrdqtyQkr8vFAGPJGc89agaPI461pSRYfmo2VRzgUAYN/EVGcVWRcGtm6jEgwRVT7MM9cUAVo1JYEDkd61oMSphjzVeNFU4wMU9T5b5HT0oAuxRbTkdatIxz3z61Xt5d5FXVQN0GDQBo6VPi4CtjnvXUw42DFcbbgpKCPWuts33Rj6UAUtdthLbv8A7pry2VBGxXByDjmvZrmMPb89xXmuu6aqXshjwM80AYxQFMiq7Jv47+1aC27bCGH6VA0flnjvQBWWAEYOPrS+UqjAANWlUkDgYpsiAdKAKbR4GRULEg4xVtyAQAMn2qVIFA3y4+hoAqW8Ly9sAH0q6GitkwSN3eq816OUhGPeqTsxOWJJNAFye7LA9lqBTFIDk4IqJn42496jxkHFAFxioiAXmoIVHnKc45qQcQimW4/fLn1oAtOxDn60T5LDjnApWx5mOKlmQiRs/hQBU3bXAINPYoq5PXtSvjnjmoGUs3PbpQBXkG9uBx71FeW7QgMccjIxV9wqqDioiwnhPGTGdv4GgDHzkjipBFvbFXBbp0Kc1f06zjaXcVHHrQAhiFpZ+Wv3z/Os02hk+9gfhW1N+8mIwMClFv3I4oAyI7NYVJySPpU1taPPMDg7F6mtIwqOuDmriqsVv8oAyMn3oAoXcYcCLcMDrUewIMKKlK7mJPWn7Bt7ZoAqBSzZNPWMZ5GKmC4bnpTgOOTxQBDtGenemSMFHHWpJpcLwBmqrEk5NAEDozsSaYLfc2MDrVoAnFWQoRQBigCXR4BGX+gqpf8AzXUmDjBrV0zo/wBapzwhp5Ce7UAQ2/K4J6dqsrGBzUSoFPGKsQnn1zQA9d3arUMRYilhiDc1oQRKhoAfbR7BUsh2jrUqKvaoZl/fY7CgBAvc96KlZMgc44ooAcV2xEiqcig5zV+b5YgPWqjgY4AoAfYAITgdRWiSB3rLiOCfpU/mNty2M0AOk2ZOepqq8Yc8GlkbJPeombgYoAhni2HOKpOSK0WkIGGwRVeZEY5BxQBms3zd6lQ5GDUht8kkYoEBB60APhLIcrWpayb1681QhU5wRVuNDkFaANKMc10emNmNfXvXMQOwbBroNJ749aANlvmBXsBXF+JYGS5DAdRXZJ71i+IbbfCSBzQBykajHPpzUM8KMeBWhHGBkt096r3bpFGTkUAZ7wgDOaqyQGU4DYFPy87bs4SoLu8EKlY+TigCTyorWPJOWPes25aSYEZwM9KYZ3ckknJ70K4J5IoAEttoz3pCignOc1ajb5Tmoy4yckUAV3izhgQcVEBg4OeKtsweMjj8qqsfmHc0AWeBGMdMVHbOPOA4zU4VdoB/KkhgHng/yoAIjvugOOtXFIcsT9ay4FKXYbDYzV3JKkDjNAEZdS5x0HpQxHUA1LFGqjgfWhlOfagCFYWmUjFS2lsI5SuDhxg5qW3O1sn0pZCQ+c0ARvFhsY5zirm1YLfnqaaAJHVwRjrUF/IMgbhgc0AOhKjJ71IxBGM1mmcdm5+tAlbcMH9aANOOHc4PUUtxliBjgelOsn/0fcaBmgCuU4zimhD1NWz2oKg8nigCrjAz2qCaQnhelPnZixHOKixxQBCVJJyaCpJHFSNj8akiXv1oAaqACkYjpU5jJHQ0iW7E9DQBb0pflcj1qtcH94wB7mtGzQJEyp+NUHiYzMeBzQBCOvSrdvESenFIiKhyxyae8pOMDAoAvRuFGBU6OQfes+I5+lW4W4AzzQBeSXpmlZssDVXPFTIeBQBcU/KKKjjfiigCe7XnHaqTLVyYkk81XNAEIGDTmanbaZIp9hQBG5wTzUZkGf8AGlk6VEw4oAYzkv1pjnNI33qAM0AAOBTGNOx1qNuTQA9WI7mrUEjABt3fpVJTzU8QLEYzigDUjl3HrzWxo8ziYAkgH1rCgVVIOefer1tc4mXHPP5UAdlEwKg1DqUZktmx1xUdpKDGD1NTzHfAwoA4WdthZWbPPSqF2A6kvworV1CAQTu0mBzmuZ1i6aUNHHwo70AZOpascmO24Ud6zBcysSGc5NMnGxyx6VWaXkYoAtCdxwXf86ljdzzuOKz/ADMk81YjYZBz+FAGg1xshO5jk9KrrcYY/Oagmfco571XlJDD35oA2IbgMNpYc063ZXnQNWdbZcjFaNjFmQEnOKANFxjr0pYOJGJ7CkkUZp8fEbnGaAK0TZZj6A1MhJB9BTEXhj36VPEnymgAiHHOakZVGD/WmqrZ4pWTv6UAV3kweKcZRJHkHpwahuBUNtwWB79KANOy/wCPdmc+4rB1K4xKcEkHmta6m+zWye/BrFv4wctHyp+YGgCp55J61NDI7MApOfaqAfa/IOa0tKXzbpeOnJoA3Jp/IgjjU81JBcMRk81SugZLv7vQVIgEY+9zQBpiZMc0hO/oapIM8+tSiTbwAaAJjHzzUT2+TwQKVbo/d6inKVdsqcn0oAjjtwWAYj6mp2WNBgYOPSlByuKY8ZUZbkdaAHK27gDikkm2jamM+tQvJkYHAqM9elAGnprHy3yec1VuOHOPWrGmkeU/1qrcnDE+9AACOPWl256niokOQKkTk9eKAJUyAKsxNj61AvAqRG6dKALa5IzU0eaghZcZqyO2KAJEyRwaKM4AFFAFtue1RlcdalNMb2oAYcYqGTOelTHpUUp5oAqvTDyDT3OevSo+nI70AROOaBx2p56U0UANbrTAMtgCpGXJGKlChVPrQBEsYBBJzVhenHQelIi8Z4AHes++vsApD8q85PrQBbmu4ohgNub0FVWv3LqSQoHYVkeeB3BoErSsFUEt04oA9K0G7EtrHg9q6CIjHPWuM8LAwWqrOfmHTJrq4pgRnPUYoA4jxtJIl1Gw/wBXyMVzEdyrEo6tz3rsvGyEwF0HIrzrz3MjAsPlPegB9/ZoxOyQYNZctmFOWc4/3am1CdkAcOM1Cl2LiMqww/agAt4Y9xGSat/Zk7VUtuJDlT7Vd3HGaAKUkTO21RjFTCz3Ku4kEVbt03Nlqnb5WKigCrDDhhtPGOlaGnoV3EimQoucmr1vxGxA596AFIz9aX7tux96RSzDtmpJ1JgVeOeaAIBjy+/JzVyFPlzg9KrW8ZNzDEfusQCfTJrUkQeYTFjywcAZ5/GgCqMA8HmlcDB60CMgk+9OK4TLtQBmzZ3HjiqsKl7lAvrWlOUHAHIqvZHNySB0oATV4jKUUZAHNUI7f900LNx1H9at3c++aRdxyOlZ5kKzKQT8vOD3oAqm3ijlOeeeM1s6TGkcbSnABHeqN3GCVdTweRVtm8rTznpjFAFWW882RthwCetX9PtzMAd2fSufJCDK+ldVoTKbYkdQBQBoR2yBQCMn6UktsMfIMn0xUsD9TTnk596AMe4TDdwR6VCu4N/UVfvVHmDGMkU2C335JbBAzQA1J8AbualV93Q5qFrZjlgRmnJE6tleooAeyAjpg1EY8DmrbKSMkc0x1I60ASacMRuD61WnG7dx0Jq7ZAFW4qqwBdx6E0AV14FOiznigYLe1PQDPHFAEwPrSjrUZ7Zpy9aALtv6YqzG208+tVrf7uamPXJoAtBs+lFRq2R6UUAWI2JGR+tOJ4qCNugJqcfMtACDmopRmpcbTSSAEHqKAKTCmnp0qaQYqFvrQBG9IoyKUg0KMUAPjXv604gAZPNC/dqKd8IcGgCK6n2qR7Vzlwzb2DHFaVzKN3rWfcI0zDYMnvQBXXl9oXcMdK2bCJbaH7RLgELn6VBaWyWmZZeG7qTWPrerrK6rC2UHUCgDcstVeTUVBYiIn5QPrXo1lMGiHtXg8V+yTo4PAbPFeveHbsT26EHIIoAveI0D2bY9K8b1SVo7qZdwAVjxXtl6Fltyp57V4t4ygMGrz/LgNyKAM6SQzQ5B/OsiS9kjUqjYOe1aULb7coBg+1ZFzGBN1BzQBasr64LDdIzY4rct7qQn5+VHXNctCwQnA5rYt5C2Rk4oA6LzxtBTgEZoErSgEGs5WHlqCeMVKrnAx07UAacTscZrUgwYRnNYAdgBzW7Zn9woyTQBZjhDIKknjA2r2FNg3ZFPlwZD7UARxkLJuA5FWQ5wDgVTjPzHjrVpRxigB2ctz0NR3HAp54xVK6csfpQBTuJVBxk0tk23zD6VQuZArH2FPhcixncnBOTQBnvestzI3bJ7U17sMu8HjpWPPkFvn4NRQy5XygeCe9AHR6bercEW45bPy5qxrtxJFCgUjk9PpWNoUTfbkfHMeSaua/IsuCmGC5BHoaAM03sm/BwR9K0dE1sxzbSAef0rntxY4xtIqvvILMvBB7UAesW8wmRZIWyDUksyxKXmYAV5pZ6nNDFneQfqRStqksx+dz15yaAOzuL9ZHZywwKhTVfLLbGrjJrlshcnnuTRHdujY60AdrHqbNjYcGr1rfs7rkdetcVa3275SuOe1btpMBjDc0AdTHOGA4zUvmxs2DWLBMQRzWgpDrkdaANG3RNp28VVktj5rFecmnWgIDdetR+e6zMO2e9AEUkBQnIxTQMVf89SBvXg0pjhl6EA0AUB70o4arL2bAZQg+1R+WwYZU0AWYRhBUzUxFwFFTrBI54U496AEQZFFXY7T5fmcA0UAUm61YtX3Db3qGRPmpY8q4NAFxl4z3pj89RzUq8rx3FRsOtAFWVTULdKsuOOarv1oAjxzQFPapUjzz2p5UIDxQBAT5a4JGazruXg81PeSAk4/Ks2Tc5O7igCtK2WABzmrVsghjMjAZqayjjjYyOoIX1rE8V6giN5cDEgjNAFTxBqDTKY4ZNo7EHpXLPLIB+8Ugnue9Tu7zE8GmlWxtlYbT60AVjOynO4Y716h4Av/OsIst8wyDzXmv2O3YEoxLdgTXTeArkW121sV2n74oA9iB3xtXmPxDsma4SQL1JBJr0e0l3ovvXNeO7bzLCQjqMkflQB5fBbpCzAvkY9ar3kduhB2jJplzIMpnOe5qPUI3KKVG4UAKEj6rGrCtK1jjbC7MY7g1lWIkdsbeBWxaqSx6igC0IRs+UZxxU0MDcFlNTQKAn1q7EPl6c4xQBWMP7xVx71p2mQOR/9aoVH73NXYNoIyD+BoAsw8seRxzSN1JqdPLSNihbJGMMKgK5jyO9ADIwcn2qdDjk1FGMHkfpUvcYoAGIOc1Ru8BCRxV1l+8fxrM1HJTk4AoAwrtiZCFq3cZi0huOStRYjxxk1b1IY04KPQUAclcRO65QVSVJDJ8owRzzW58qJyc4J4qhOdxJXCk0AbehR4t5JTjdwOKytzi9kLMCsjEP/AErVtWFppDZONwzWBIwRy5OR1oAku7R45eKzZUeNz8pP41qQ3P26IwkgTDlD6+1Z90rQZ9cUAUjLIrnJJ9sdKcrkqQWJJqJbphL823J4NXAIXwTGD7jigCEyEHJPTtToZN0gAPXsKWW1imYGFiMevSp7a2Nucx4Z26mgDQt4hFhiPm649KvRytng4FZjO4YcFc1ZhcbAepoA2be8kQjJyK3rK5V+h69jXLQsAMn9KtQy7e/zdqAO3tTwcVBMnzsQe9V9DuWkVlkOSMVecBnO3nnmgCA5Cr7UgJ5wcVc+zNInYUiQRxsfMPPpQBFDLKD8uTWlAu//AFqgVUa5VOI1pBNJIeTj6UAbAhiVcqBmopJmBIC4FVInKHgnmrkdwrDDigCrLO4OCxoqSe1WV9yE4ooAklUZ4NQkVZZcpmom9qAJbY5XBqRsVXhba4qxIcjNAFeQVGsZZjxUxGTmpMAKAO/WgCDbk7RVa6fPyJzVi6fyoflyGJxmmWUIf535+tAGebOVxkKarT2kiH5kIXruFdMVCrjIqlKQ2UPIoA5i8l8qNjnCgfnXH38ySSsx5JJ69q3dflYTmJScDOTXOXIQMdxHT160AVpZSU4GB7VTRy7NuDcetJeXIQERnArHlvZQ4JY49jmgDb8yJOHcBvftWn4f1COHVYeRtbIzmuHknaUkknJqayuGgnSQMSEOeKAPpbSpg8KkHPAqPxFF51gwz1B/lWR4TvFns4yDnKjv7Vv3i+ZaMCBQB84ancyW91LFuOY2xzTodQlnQqrEEe9S+ObU2mvzDosmGFY1lII3Pv0oA0HnnjRiZWyxyOasWepXCyrh2x6ZrKuc/KW9e1T6eS8/qAKAPQtN1BZoFyACOtaUUu7JHTPFcjYOFUEcGujspN69aAL27AOe/rVyE5AIrHkZg5yRitCydvLFAGsTlFUelOXhQKjgDFc5yalzk0AK3SkXrTTmg8AepoAdM2UOKyb8Ex5rSkOF5OKzNRfEeRzQBjSFt3FXNZk2WcY+lY013Isp54zgCp/FFxItrDxkHtQBny3UaBgxA/GsxNRiedYgm5yQKqu+8OwUE4z1pPDkP2nV0ZgCFyx9/SgDofEt+LSzhjCA7j0rA/tZQCrRjkcfWpPGE267SMYwg6elYUKCRgGJBPQgZoA1Rfoo3Mmxs9Qa0ZLiPUrUyRH5wuGXvn1rGS1DKY3OWWmCb7NIhj4KHj0oAguZXjdk24I71p2DhrRfMfnoQKbchLyAyxDB/iUfwn/Cs2KWWFwCvHpigDoiwaEBcKPaliIBA3Z+lYb3Epxgtj/ZNXbacrtzye3tQBuRynIGzj1NW4xGRyADWdaTM/AUyP6Dmt2302SVQzssanqMc0AVgpXAT5qtW9tNIf3cbH3xir8cFnbAFyHYepqwuoKRtjTAoA0tFtWhVjIwDccVqJNFHIQCC2eRWNpckju5dy3Snb9l5J9eaANwzFjgcVQvgVkR+ozyasRMGVT3onj3oRQBX61YhX3qCPofUVZjFAEy9qkHSox2pzNhPwoArtKwdsMR7Ciod2eT1ooA3RynFQsMVLEcjFNcc0AQng+9WVYsozVcrk1NCML0oAcB8w6UsnXOBSgYamTHAJoAz798naOg71Ys3DQEDrWbePznrVAXDwZbcQv1oA6OZyeMGs7UblbK2aSQ/NjCj3rGufEEqqVQ+2SOa5rUL+a5YiViQe5NAFfV9Q3yNjp3rAu5DIMr1HWrF1MuSMZxVHczMSiE56gUAV7t8wrkgn0xWO5yvoK357FnQMSEB65qNdGjKbi5P14oAwAMjjOavWNpM5/1bbW4zW5Z28FtIEjiDuf9nJq/e2235pp1gT+73oA7fwAHWxQMy8YH6V3sa7k257V5L4GvIIrmSGJ5nzgjIwK9UsJFeFTz0oA8t+JPh9ZruO5Zn7KcelcKumWyXIVpHx717t4tsoZ7GQuXXvnGa8sn0p7mVWtZUlA6r0NAGDeWVuQqmRgo7mpdO0pU/eCU4PA4rQu9ImVR5ikH0NLbW0sKhHDYFAEyWTxqCjBsVpWAdVJaq8SttHrWhAuIwT1oAkA3AAjmtOzTCYqlEuQCeta9om5fpQBbtlGPenheaIVYZ6U7HzcUANZTnmm8gYFLznkmkHWgCB1JU1Qu0JQ1p4zkc1VuVLIQooA4q+G27HpnNSeLAfKtwM5IrUubEGQF+pIqHxJHhYRtB460AcbDG6FgVJzxWr4UsmS5mlKkYG0CpY4sEEYzjpW5ArW+nSOAATn86AOL1iwubq6nkRMjPr71Rhsp4nUNGcjrXSIzeblwQe+KY3zucZB+lAGRPDIAsm1s44+lVGAMoDA7m68cV0EoIjPPC1WV1IAKjJ74oAqW2+GcPGuUIKt7j0p17aMCr253QcgEn9DWvZ2z3C7IY846nFacOmWtkrNctvB6o3SgDmdPsTd4WNWL/oK3IPD6RBmu5MDHQGr8twIrfOnohTkAjisCaS4nlPns5OenOBQBrrfWGnJstRk+g5qndaxPJ8qkKh9BzVUxApgqPyp6W6nnI/KgCe1uWzzyD61s2ZSTAU89cGsSNCeAnTir9srIw7Y9KAOu0hGBbPoKkmiBuH7GqmgzEswYcYHNaLrm4Zh92gCxb7gihutWByvFV4verKL8lAFZEIdhUyfrRj94cVIy4FADgcYomP7sn2pASaSX/VmgCnRTsUUAbcfymlYd/WkBwRmnuOBmgCHByaenelC8Yp6JznHFAAAcbj2qrcy54H5VcmPy4Hesq+lWIELy3rQBQvZEiXLHJ7CudvLl2PUlfT0rQvJNzMWOTWRMGckRj65oAozSkk9jVMq0j8jC981pPFGg+YZYdapzyZOCPpQBm3VpGpLZOfT1qvgE7YkK464HWtVITcEgjgU4QhcpEAWH3iegoAxljkLAMCfQCrptPKAe5kREIz5Y+8aZeXogO2yYlhwzkcg+1c3fXrl9zOfMzQBu3F4qOPsaLH23dSfxqjf6gFVWfc79yeawXuZXbcznNWYLgyo6y8rQBveGdQ8vVo2wQreh6V7Vod0JbdAPSvnWAy2kyyAfKOc17V4FuvtGnwS5OGUEUAdVrgElk425yK8SmnuYtRliWYhlJwF4PWvdbkB7Y8ZrxfxxZpb65DLEpVnQ/pQBKmpyeWi3KiYAYJY4I/GrdpPDckLCQ2BzG45/OufsJ2kJjkAKZyCetXBAYrpZIwSKAN4xIAMIVPcelMaRFIWrttMsqKs3XHDehqnc27rI2Rj6d6ALNtlzweK2rZdqZrFsTsI45raifeo7YoAtq5wMcCpcdTVaM/MB6VaY/JxQBCwxQF5BxS9aemMUARkYDe9VZhtBOByauEc89KhusCPgd6AMq4Tc4I9apeIY1dYw3GM1oyH5x9ap+InXbGuMdeaAOYwTMFRj1x1rY1aQW+m7C2OQOKzrKASajH12g7qd4kheV4kQ8DmgDNWeMt1YmphNCkbPgk44GaS2tFjXkZbHertlpUlztLqVT1zQBmApKQqo7MecCtO10aMKJbp9vfHTir8ottNj2xqPMxx3JrndWv5ZyQ5+U8BQKANafU7azzHaIrEcZHT86zppJr9su5I9M1Qt0KoSFwKtQymFAVJH4daALtpvichgTEeCvv61aYKcbVB9apxyySR7hV+y4UO4x70ARtZrKhYApTY7JlAxggVpMBIFZScU3JQ4HTvQBTKBDjGDT40OQcVdwHA3dKmit142UAXdCUh2zxwKuvIUuZMcj0qvpIAlcEYOKkuP+Pls0AaMLBsMPyq7bkHKmsaF2RsrWtayKwD/AJ0AKy7XPenkZAqV03cge9MXp7UAR/d4pspO2nuuT9KhmPzYoAjJopSaKANZmwalXlahYZNTQjgigB8S7mxUzkE7V6Uka7Y2PrTHPlwtJ6cUAVr2cKuxCCccn0rBuWJJ9TVx3LFx3NQPGMHdgn+VAGRMmQS35VnzuwyBjFat11Pesu7xHkvjHpQBmTOWY5GP5VSlmjXphiO/anXcpuHZEGFHes+VduU5K+lAFqO6WR8GQIgGSR3qpf3wlTy0OxF6+re5qIJuHHHvVG9hkbPlg7O5zjNAFK5vFiBCZZvXNZUr+ZIzkYJOauva5PzygfQE1XaNUU/IzH1NAFep7fexCoDxzTFDHOMD6mrVkg3/ADt8ueTnigC5BbvPkSSRpnt1zXpHw/k8u2EJcHy+OOwrywyt5q7W+VTjrya7vwPK6XPzEEOB0PSgD2O3w6YJ6iuA+IWlK6pKCwK9wPeu4098oMGqPimwNzp8oGCdpwaAPILS2i+0riTnHQjvW8bdo0G0pjrisi1t5BctvByDjmtufJiI9KAGrHICGQhvxrSsy3l7ZlBXtz0rEtmkRwWJ255retirxBgMj3oAc1rtkDJkr2NXIwQBxT7IA5VuVJ6VPJGFJ44A7UARRkEls9TVlTlTUCIFbg1ZQDpmgBgODT16GkIUU4Yx16UAREk01hlTmpeM018YoAyrlcSjHrVbxDGGSMnpzWjOmZAf51DrcYMScUAYmixL9oc4OFXrTNThNxd7VBOOBitXR7cGOQqvU9atpDDbqXcKZD370AZ1lpaRRq9xgkc4puo3vlIyQKABVtmMjjP3PSqt1BG2WIFAHH3c7mc7twz3NVQrMpJJI61v3tmjtvVQV9Kz3tmLYU7VoAqLclQFGCKeLgdNufanC1KBmKg96qtjI4K5/SgC7BMxfOAAetXllY5APy+grJZlSMHP45p0F3hsgHHQ470AbkMrINjkmI/mv0qd2aIr0dfUdxVZCrxAj14qxahVHlzAlD7/AHaAJ43jkIIPPpV1cgeg9qpSW5j+5xz17EVNBLs4kyVoA2NKb523Y6U67U+e5U/hSaYF8wle4p17kztigCFZNvU81bs7grKpzx3FUwofjGG7GpYVKNg0AdMrAqpHQikcbWyBwaZYnfagZ5UZqZwDH9KAIW5GKpSn94av/wCFUpl+cnpzQBHmilooA1u3vUsPX61HjJqWPhxQBaIAVar3fMRQd6sMeBxVa7wo9TQBjn92+O561BICx61ZmBLA46Vn3lxsLKoB96AKl9KkanafnFYE5adznPPWtGc+YSACTmljtScL3I/KgDLh08Ocj7g5Y1Fc2scsm8rhRwAOwrWu+IxEh+RepHc1i39wEBVOTnmgDOv5IoQVQ7cVgTXgEp3kkjvVnUp1AZpCucViyXKO+VXHrmgCWW9/h28etQNONpB4B9KpscnNIfagC9GbX+Pdg+h6VclktGtdik9eMetYuaM0AWyypONg5Fbug6s9tdxkAdcHiuZViOlaFij5D5O7sKAPofQZ/NgVuORWzeDfasB0xXIeDbgS2cRJByK7NV3QMPagDyq/zb6lNG4GAxxxUyrHMoHIzVzxVZNHqXmkHDdKzICvIJ5PU0ARyBFbG7I7VfsSMMAePSsq4iPmBgcCrtm23A6cUAdBaKMZFXF+dNrdR096o2bgLtYjFXj/AA/nmgCNo8tyMU8KM45p5wwX+93pSuF4oAjdAaYV4NWtvy1G64FAESqSKHTjk08cnih+nSgCvJGDg5pLy185V/u96sxR7xzwKW+kCW5C80AU8LbWhEXXFY8nmOwLn8q0byTy7NTjk1ky3YH0oAfIfLH4VX3O3aoJbwPIqqNxqzK+yEMcDigBjDHBXrVG4geQkDgUpvtkm7OT2qxHeF0JaME0AZk8TRIyg8mqSRHDFsGtWaRGyx+U+lZs3zMfLORigCFbWO4z5nyjphTUv2ARDEfzD9akt4j0b+VWY+Sc9BQAy2fy/lIIPXmrZw+Nv41AZd2Ayggd+9WYo14KH6g0AXLaXCBJPmjP6Us8YUhlOVPeoSDt5GBUttMq5RhmM9vSgC5pDYnxk9Kt3kqi5w5xkcVWtYtlyjKcqehpNXGblT3x0oAtAYORVmEblwetZthOWYI4x71rxDj1oA0dKOAynsKugZyPUcVUsxtx6kVbB6kUAQjn1qBxyasPw5+tV37igCsw5oqVhmigDTSpQeelMWpFG4gCgCzHny8mqlzlicCrvRQAOlUL5vKjJ/i7CgDF1GVlJSM89zWWQWJJ796uToWJznHrVU5LbV6UARCPbyBmlnYwgxofmPLH+lW1UQx+YTwOFrMu5/LBYYJPXNAGfqEogjJdxnmuL1PUsswViD61pazeM0rZIwelcvet3GM0AVrp2kXLMSOuSKpk+9TMzFgWyUHbNRSEE/KMCgBlFLQFJ6CgBKKk8pvQfnSbTnB4NADK1NJnJfymyRjiqAVWdVUE9jXZeGdIjVBLMmWIyM9qAO6+H6tFZKjEswJ5Nei2rfL83TFcHoUyxTrGmMEcGu3sW3AGgDC8aWpe181R86n9K4dCTKAvSvVNahE9k6+oNcAIo0bJXBFAFOWI4GRkVYtIQQD0rSMccsY+WljgHGBQAsUe3jrVrcdwHbpQseCKkK4c+xoAUcD3qTJNIq5qTYcUACcjrSSjHTmnrgGhh+VAFYcVIibgS3Qc1KkOeT0psrYyo6UAQTTY4TGKjuMNbg7fSkaMkk9qmRC8OCOBQBi6222ONVGK524LEjuM10+qxF3VewrHurMK24nC0AZ8ShZM7QKtY80FT0HvUbIMYGc00Ryxjcx4PQUARvaJhsfKTnB64rrrDw1p/iPwyknhGJ4vEumwA6lpRkLm/QdbqAnkv/eQfQfwlun1rT9NbwzqXhWCwtk8QaJplvq090sY813Ys88LNjJCRSRkD1HTivL7G6uLK/tr3TbmS1vrZ/MguIzho29fcdiDwQSDxQBm3Sb41eB8huciqqfKcMxB9q9T1PT7b4jWd1rOg20dr4wtk87VdIh4W+Udbm3H97+8nXPvgv5iY0bL5GOvWgBUkZuAxwDVlHHl8Ln1zVJsLEssb5QjII6YqOGaQjIPegDYWASDcg4ParEEDL94Yx61SsrkHgH5hVmK+G8hz7YoAtqcEnqPSphHHIMhdrdarpLE2ADjPrStIY2x2oAt2cjw3CqfmQnpVzVod7I6cLg59qoWkqu6n3Fat/uCoU5B4I9aAMqAkNg9fatmwkOdr9O2apC2AG+Mkjv6ipYTtI6/WgDfgOGFXSBgEcDvWZZyeYgH8QHPvWnFygBoAru3zmo2+8aSXIds0YPWgBpFFONFAGmF461LAvzE46U0YqaAHy3OaAHrjDse3NYl2S7ZJNbMmFhb3rIusCgDNuG3AjvUcUAP3sDPJNTSRjJYk4HQetVru4MSbAPmPX2FAFK/mMsmxOEHAFYeqvtyAeBWpKQkZYde1YN8zOeVzmgDEugsoOeozWBfoCSoBNdWbJ2O4nbxVWW1jQg7cn1PNAHHGGRiAiMfwoNuETMjfMf4RXS3C7gBjBxxms2W33M27j3FAGQAQflX86cI2YbsHFazWGAGU5THNNkMNqoEuSDwBnNAGT8275eMelWLWHcxaRsYpjzJvO1cCozKcHHFAG3pcIebBVSAfTrXY2RKqq4A44FcHpE06uSrHA7VuxXM7yAZO49M0AdrpzBbuJi4AB9a9B06QbMBga8kjt3EIkYkEc5z1ru/C1558a8+goA7NgJISD6VxN/AqXjpt4znOK7e3GUxiub120aO489cr2NAFG3jAQZFSiP5vQfSnWzE/e6n2q0eOg9qAIY0+cUpjOeKnjXnpTce9AESqQeak5qRR1zSlcUAQqTmpACX56U5I9x4FSsMLgdKAIJG7DpVaXHQVbZB2/nUbxrxxQBV21PajKlaUoAc1Narh29D0oAyLxR5jZ5xxWdOsePmAOK2LyPMr/Ws24g9qAMySJXwdoX0HrWp4UbSrfxDYTa7IYtNt5fOnKxtIzBPm2hVBJ3EBfxqtJDtXAHNZF2JIyxKnHqKAPSND+Kl5N4hi1LVPDnhO2ivJf8ATZItLcXflPw4Mvmcts4JK846V5vqNrZx3V4umXDTWsc0iQSNG6GSMMQrYcBuRg8iqovgJMMDj0qTzhJhSMbuhoAZptze2N7b31hcSWt9av5kE8Rw0bf1HYg8EEg17J4M8Kaf8V9W0/xOLP8Asu8t7pf7cthC32W9Iy3mwt03MQA65yMknnBfxxoQxGSQysGGD3ByPr9DXrfhH44eItDiittcs7fWLKNQgdALedAOnQbG47bV+tAHBfGvQP8AhEfiJqtikQSwum+22vHHlyEkqPZXDqB6AVwSnzTuAwvtXu3x28U+EviD4U0/VtLuxBq+mzbJLO8UQzNDKQpCjo5DbD8pbA3e9eLraq0YWE49fSgCsjhc7OppSzIc4yfehrV4QWIO71BzUsEXnp8zdKALNu5eMYxkVKLgqdpGVHaoYrcwkFDxU0kZAyAD3oAu25UqHRgD1x3roJH8yziJ68Vxo3Ag8j3zXVwMJdLQk9Fzn3oAltyQ4IPPrVwQB13KOe6/1qlakMRuIwf1q+khRgVOMd6AHwYjcY9a2EOVBHQ1lgCZsp97qR61pWOTCVI5FAEV4OAQOoqFcso45q5crmL0xVXGKAEyRxiinY96KANQDjNWIfuH61XGcVZi4Q5NADLziDArHl/1e5zwK1LpvwA9aypVM/KjjoB70AUcklpG6L296y7hy8hY9T1rS1FtmIkHAHOO5rNdQqBm4b0NAGdd7pHwMog71WKAD7vI71Zckudx49KqyfLnaTQBTuGwSQOprKu2O47WxWjNOqqd6/jWTc3kJ6/nQBWaZ3O04JqCVVzk57DimapdIrDy+CRn2rEkupixzIQPQUAaUzsjAM4AHYms+8lVgqht+O9VpHZuWJP41HQA49c0gGTgUlS2/wDr0wMnPSgDd0e2ECky5yeQKv8AnpHI+PvdR7U62jwoaQAk9hTriJSAyxkt3OKALMOoyTQNERwK674fysZnQ54YHmvNTJdpMFWPA9RXd/D15xMXnyN5AGT2oA9htTgL71W16DzLZjjpg1JZNmNfartzH51uR7UAcUn3xjOKuKM+pFRSQMkpUDkGrcULbMkc4oAiQ43H0FAOc1L5ZANMjXBOaAFXjn1pygscY4oEYLYAqUgRrjqaAAjYoFNJyvajkjmgCgBByajlGDUmKZIuRQA1iNtPt8AZ7VDIcLTkbbBmgCG7wJCcdaoTsc/drRuwDGrCs+agDLuJyAe1YepSl43Ylsj0rbuIie3Ws26tDsPpQBynnzCXcgb05qxHquGwyA9s+lTXtlk5U4IOeKpC3VVJUZP9aANm1u7eXkNsPfPer5JbaEKkVzkVrJvBHftW/BbSsqjke9AFS7g3lg0YYHqCOKFjwjDOD6VorZSKcs24elSQwKGw8YPvQBkmKUDGCwPenx2zbcyR59x2reS2jbhcA+lSNaYwFxxQBz4t5cHa3GOFqFkkIAZGDD2rpVtcHJUU426kglaAOVdHHUVvaMWk010CnIyMVaewUcrg57Va0uHaHTbjNAFLTmYJtccd/atONMJ1yDUEMBUygDGDwatwRsByRtNADoT8wwelbVlJvQg9cdax9nlSDnKtWrZALz2NAEs6ny2XHOKonjArSZuCH5GOD6VUeI9c596AIuKKGHNFAGqmWYAVMG+baKjiHDNSgEBmPagCnqL5IjU98mq8Z8tC54zwKlP7yRiTwOtQk+Y+5uB2FAGfcxnfuYVk3m4uRW5c5JJ61mXWMHIAPWgDGm75rGvLyOFsEkn0FWdTv4kBWM/N3Irkry8LuQq+uc0AWb67aVCSRsycCufuzI0h2fz5FST3UqAZGV9KrS3aybjlkPoOlAEU0jy480bTjrUByDzzmlaRiMZyKnt7OaZd2AkfXLcUAVD1oAz0q6beMnEZZiO5HFWYrd4ydxTaR2WgChFayOR0H1rZ0rTkjnDM+6QdAKhSSKHO5kLkdcVJBfqmPJ5Y9eKANy+kFsEPQ4z0pkNy8sOQv09zWZfXUrKrEcd6W21BBDtZgB6Z4FAGxZWzXUwWTr3xXY6Kgt2TbwARXI+GriGVnfeS+cfLXX20ytgAHjvQB6Fpj7og3qK2YW3Jiua8Pyh7ZOe1dFbH5iBQBhX8Wy8Oc881NABs7/lVzVbc71cVFCgwM0AVZU2q1QhK0Zo/lIAqEQBFznmgCJUKLk96icbjUsm78OlROpzxQAuMYpMc0nzAUDNAAyHtSMDjmpuwqN8nigCtIpKmllUrbAVMV45pLrAjAoAgx5ltx1A71muCTzxWpan7y54qvcw4l4HFAGYUyCKrXFsxXAXNbHl4HH8qGjLD/wCtQBystg+wjAz25qimkvkkkY7gV2Jt+cBc1FLanB45oAwre3SHtk4q0OucVK8DK5GDUiRMV6cj2oAaEDqNvWmtb7eauJF8uMYpwjB+Vz+NAFCNSG6Yq2jcY5IocKnWms20ZUCgCwIwwG39aQxYPOKrCZ+3FTRy7hhx+NADgFHWrFmV80jHUVFt49vWprUYlXvQAydCskgXp1qNATxV6ZdtwrHuOaQW/wAxwaAI4l37V7g5rSXAQYqFIwuMde9TxjtQBKeY89xVaOQr8rDg/pVkHAwe9QSJyfrQA2RDnKjINFIHZeAaKANFD+5OO5pXJEDcZzxTUGIEH1pblvLhQD756UAZ82EBVeo+8arGQHHY1NcgKp5z71nvnOSfpQBJdNleOOK5rVrwhXjjJHYmta+uRJEyxthh1rm73P3jigDAvVLAnjOOK52YNvJPykcYPeumvDlWz+lZ0umGUgzEgDpjrQBzNwXZtgUnPHSmR2ErjP3R710z2qQj5CQAOT3P1qs8qkMFA56CgDNtoI7f52CuwPfoKS81DzUVYwBjjgVcFl9okTBCgetI1pbQzscZx37UAVInYRgvwPQDBpklx8pJAx6E0y8uwx2oMds1QJJ60ATSSiQ8KFrSso1jIDhQp5PNY4OKngYyTBpHPHOTzQBf1aUBVjR89zg1mx5IK/3jVi5WN8ukh3ehHWrFnbK4iZyT83QDFAHXeFbAwQ5IwevFdTYj5gD+tR+GoogMsM4U9a0xCFcMp9z2xQB0Ph87SVxxXVQnBBHWuP0mTbKv0xXXW/OKAJdQTfbk9xWdDnitplDxY9qz7a3Idi3AB/OgBdnyFjVOcljx2q/cNuXAzVJhxQBCRx0qMrVkgYH+FQn71AERU46UoUDipT1pON1ABjjpTCBnpU8YBHNQvw1ADGQcYqO8TgVaQfMKju1JK0AUohhhgVJcx5IanKpU8Hip+Hh9ce1AFAIMjFIyc1LvAzjFGSewoAiWPnpTZohmrSkdD1qNgCT9KAM+eJQM4zUcYBz8tXHQHOarY5IoAaUJ4BxUMyMMD9atKSKHXJHYn8KAKB+f73am+XxzmrjqM4IApjRdx+tAFbaAK6xbXwtpXhvQ77XYPEV1eap9pKR6Y1vtUQuqknzSuPvr0J79K5dwQTnpXqmkw+OZ/AvhdfAlzLbwf6Ybx4hbElvMTyh++B7eZ90fXtQBw/iy1sdI11bGwmnliks4b0JcKBLAsu7akmON2Fz9CKzYjskUjpmtz4iTxxalo9pfSWVx4qNtLJrUtsI924Miw+cYwF8zbvyABwB2xXPRtj6UAad0m7afwzT0x8pHWiVgIVJ+7T0T93+PFADmX5QRQp5yPWpIxxg0yUbfmGaAJHIKAj8aZL9wOPxpbblGB5780uMxuB6UAVuvcUU36YooA1gVSBGI5GcCo7k7og5//VTY5DMilh3NJct8gTtQBmXRDHGRxWPqdyIYyiHDn9K0dQlFvGxP3ugrlbx2ILZy3egBElLRkDPFVpP3xIUcjrU1iuXbP3aLokOfLGB2AoAoNAkY+Qbm96qSht5DdPpWk/zJlzhvQdazp2A+9wT60AZ1wCxwMAe9Z86RRMSdtS6jeJG5AGW9qwLu6keVl+8PSgBZ75kdtgGO1U5Lh3HOM0yRSrfMCPqKjPJ4oACcmipRHgnJHFMcg4xmgBlOQ7WyBn60hpKAJsO67gvGewrZ0iOSVAGKgqRxjmqVjh1JI+SMcD3ot5pBeBY2OGcE+3NAHrelQ+XGuG5PtW1FGGPJrF0mQNEhOeBW1G3QgcUAX7fbHgg9DXVWbBwpB4NccuSwxXUaQ2UQelAG/ajdwelQ3ilWwnHvU1ucMBTr1MgMBQBmbDsPrmo5EHQDpV2MAA1DKgzQBSdcVHt+bpVt1GKgdfpQBCwpoHNSsOKaBQAi01lGc1MF9aawFADIyNwpZySwxiiNf3gI6VJKozQBRdW+uafAMZU1KV4pFX5xnNAFd4gHIppXFXJ053YqJl4oAr7ec0hXg1Mw5qPHWgCuyZ7VUmXa/FaBFV7hPzoAqg4JB70FhjBphPzZFDEdKAFP1oJwOT2phyOlRXimWKILGswWaKR4WmaESxrIrPGXXLLuUMuR60ASsueap3elWN7IHu7O3nkAwGliViB6citwX+mDiPwNoSj/AKbahdTn8M4xQdUjH+r8GeAVP/TbRmnH4AyjH1oA5+KOx0+MxxC2to8/dTagz9BXSeAfD1p4y1W/0+z8QpaaosQmghZUmidV4cFQQwPKchu5OOKdF4g1FObfTPCFmcYBtdBjXA9BuZuK6z4eeNZ7PX3n8Ta3p1ppVvAzeRHZRRF3Y4RY1Rd5Jw5wM/dPFAGXr/gvxTocDC90eS8gX/l400m4XHugAkH4KQPWue0y8huPMWOVX2HDKDyh9COoPsa9J8TfFrVNRjli8LWv9nW3I+23iB5m90i5VfYuT7oK8yQNNqU1/eSy3WoTjEt1O5eVwOg3HoB2UYA7AUAayjBzSSDIIINR2km9MHqOmamlyKAIrcEShex4qRBy3vxQi5dD3Bpyn96R70AUjRSuPm60UAWLI/Ix96dMdx56AZqK3/dwID1PNLeEpbuTxkcUAczrcnmzMQT8mQKwgkkrZ5A9Sa2LlcuQOc9TWfcsF4Xk+goAijTbMvoOKku3ROT/ACrOuJzvXsaS9uUjt9xbkdvWgCpf3Yh+cEAVzV/rCSHbuOR7dafqt8ZwWVccdBXPBC2WYcdaAH3k8kwBxwO/eoIkbzR+eQabLISCv8I6VEm7d8uc+1AE9zJufDMzY9acFiZ18gOzHqPSlhtC4aSZtgHOO5qxGAABD06cf1oArsgLdwmTnB5NP8pUKgYUHkljzTrm4SMNEiKSO9UZJGkILH2oAluI1D7kbcDTRFkLt5JqKlXIOQSMUAa2mQHy384fJ6ZxTgbVbtFhBLbvmx0xSacWulaJgVLc5FatlpPkyNIxDE+1AHZaZcgRLtxz7VsQTOQPmOK5uyOxQBWzZPu4/CgDds3kkkVVPJrrNLxCqq33q53SoBbp5sh5I79q0bSffdK3RewoA663OSpq8wDRe9Z9ryoNakS5j5oAysAlgajljGOCfxqw67ZmFNZcqT1oAoOmKrupzxV2UEHp7VX288nigCuyMcUmG3cZqVwSeegpFHT2oAbyB3/GmHnrU3Y1GRzQAiEBgBUko5FNRfmBqWQA4oAgIGaO1OIAOKTgHqDQA9hvj+lQleKmjPY02RQp+tAFcrTSvpUrLzTSBQBAycVXmXirpGaguFwMigDHZNp5z1pjYzxVp15OarvHk5FAEW47valBHXFKRg01RjNAD1c5/wAakU54PWoOc0obHWgCxTDFGJjP5aedt2b8DdjrjPpzSI+Bintgj5eaANK0Ia3I96qwR/v/AM6tabgxtTFAFyQKAEh+Uj1FaG7zIww/GqOzuKngbb16UATQ8MaQjEpNSbduD0zQ6gqW9KAM+TG48UU1zzzRQBcYqJMDoKztfuREiRjJYjPWrUJMs59zWL4ibfqH+zGPzoAzpWIHJ+Zqz5Qw5I56Vbdt3NUL2dY0Z3z7e9AGLq832dSf+WmOKx/tbXFsRkluc0upzvcMST1zn2qhacb0iOcdRQBCyBVO5vmKng1nTXOVMUUeW9a0L1XZzHEAHxy3UVDDbx243Enfn7xHSgDOW2crubCj3piMEkBHNTXs252VWyM1XSN25VWP0FAEqv8AKeSDn17Us02wbY/lJ5JFWLTTbi4OCNo7ZNI+k3IndCFyvfNAGeTk80VrR6QeN7HPtVyz0SJ1yzEke9AGBEhdgACTWxYaNJPIfMBC9sVuWelxRkeUmTXQ29goOSCPWgDGstNjhBxHg9OlWrdfLlMZX5T0JrZa13RllwAKzLhCsgBBLA5yKALVsmHwe9b+iWbB2mmGFHQHvVTRtPM0qyyf6sd89a27qX5BFCOehoAsvP5zbVGEHQVdslO5az7SJtig8Vs2sRBXNAHUaf8ANGta1vwCKx9L+7jPStiL+dAEFxHibOKgC4BFaVynybh1qps+b60AZ1wpz0qsy4zWrcJxmqDrycUAVXXPSm7ealcHNMNADdtQtkE8VPUZByaAGqDkGppV+UGo1NTsMoD/AFoArEc0zHtUppuM96AGLkMD2qWQblBqMjmpYySCKAK2SM5oyCae6YY8frTSuO9ADQKikGTUx70yTigDLuFwSKgUYqe5b5jzUAOT1oAa6564qExkE4OanY0hPvQBB06ikcjHvUjoG55pjJgetADVzUsRIPp7VGq1Ii5Jx1oA1NM++wp7JiaQjsM1FppxKR3xVqb5WIP8fSgCFemBUqodu6mqhBq0F+TmgAQ74+eopxOIyD3pkPD7exom4fGeBQBnS5DkUVJeDEvGcEUUAJYD9+TWFrjH7W31Oa6PS05ZiOAK5/VIS1zKT2NAGJK6xIzv9zGWrmNUu3uZAV+6eMjtWv4gmAH2cHG3l/6CuWnuI7dGABJP6UAQ3jbYtqkc9zVfTRJ9rUtwo4xjrVoW5ZfPf/VjkAnrUttbyyyh44jns3agCPWVRXDIPmA6AdaoQ6TdXq5c+UPTHJFdta6MmwSON0n94jpVyOyAOCBQBx9h4dgiG6VTIf8AaHStF7KNeEQce1bs1uQcKMD1qAwkHAHPqaAM2C0AHTntVG4tibg5z16YrqIYMketV57ICZiT0OaAMOOAk9PlHqKmjtlByDg56CtXyVdcDCimpaEuAvJ6ZoAbZQYYtuwo9q2IVMigjuOwqNLMJEA3U9avxKEQcYIoAqPG3QEY70W+n/aZQuOOpOKtLbvJJgfxVqxRLZW4BGXPcUAJ8ltCIYgMiq8KZfryTToRlyztk1KWVCML70AXbcdBnpWtDjisa1nDH7vNakM67gCKAOh0w/Nj1rbQHA4rn9NYblOa6KIZWgCwQGh6VUVhzwMir0Q+UCq7xBXNAFafBU1nSbQa1pY8qazbiE5yOlAFOUKQMEVCyc8VYki45qIoaAI9mOtQv1qw6MB0qBlIbmgAX6VOOYqjC5qzEn7sgsKAKbDsaQjHGKmIAJHWkP4UAQ446UKQG61IehphXAzQAsw3LkCoCeoxVmI5XB61C6YbFAER9aidqmPFV5Bkk0AZt/w2ccGqeTjNXNQGQDVAH5ec0APU880/IOKhHHU04EjuCKAJMZ+lOAzxTFYHvjHanrzQAhjFC8H3p+OacybsY4NAFjTz/pK+pFW74YkTI4xVewXy5FduTnAq3erypNADYDvxnqKst6VWtVIbdVl8EZFAELHGCOopZ8YD0xzlsU9gWgHPSgCF1EqqSKKdbvlOccGigC3YxbLbnq1Qy+GdQvpDJBEEjIzuc4H/ANevUdH8NR2eHlO+XbjGOBV25gCjAFAHj8Pw2s3TfqkssszcsI2wM/XGajuvhh4ekQhracf7QmOa9QvDFAjSTOqIvUsQAKwf+Eg0mS5SGOberHG8L8oP1oA8a1zwFcaXdiWIebpa+/zJ6Z/SolsAiDYowK9+ubFJoWR1DIwwfpXlmvab/Zt9NDtJjzlD7GgDn44wYMDG4elNaLCjg5q/DF1WkkiGMUAZciZj246VXNuzdjitdosj605YwFwBQBmxptwMYxUV5CSQcGtqC0DHirT2KeWCwywoA5eO0ZzwpxV5bZY1Xbx61rCABumabJbjd1zQBnrFkjAOBUnlgttxx7VdSEetW7a1WPMsg+lAEdrELa2zJ97rWfNI08zNnC54GKt3TNK/otRBMHpQBDCm2QE9KtSL04pFTnirJTKDHWgCvbLhj61pw4GDg/WqkUeWz3rRgjyKANfTTyOa6e1OYxj0rlrJdpGRXR6e2RjPSgDTtzgjOaLgc9+aWPjHFPuF+TNAFJumB2qpKuT61aI5z6VHKueRQBnSJ04qu46dauSg4quRnigCAgYNQsAatSJhSRnpVU560AA6YPFTQL+VQEfnT4OGzQAsy4fioiPWrFyuRngVVI7ZoAVvbNIaXJx1pM5oAQYDcU+WPcme9MPWpI3x8p70AU2XGarzjCHr1rRmiwSV6VRuI8k880AZd0CyfSs9lPA7VqzR/KQaoSJgkUAQdaQ8Dj8akI4ppWgBoIzkDmp42zwetQ7SMGpB6gd6ALK8ipok3N/sjvUMfzAA9KtryoVQAB+tADsZcFe3Srl4paJPXiqajGAOtaci7rZWPUDNAFUlY4hzzUSTgtt3dar3kpJIB6VRMmW4YgigDXc8+1SjBtzjtVVH8yNT61ZhU/Z3PYnFAFROp5xRUfc/4UUAfSFxEETJ7V5x4y8b6doxdFY3NxyBHGRgH3Pau88axXD6FeJZkidlwmPWvla8tpLrWDbkNlWIk+uaANWbW9S8S6jI93I0dqrZWBSdoHb6n3rYt7Y5AwPwosrBUhRYxgqOfetSBPKAYjmgDtfDs5vNNCv/AKyIBGz39DWP410n7VaGWNQJYhnPqO4qfwasxv5NqkxMvznsPSui1KMeU+R1BzQB4dGuyToTmnyx5PSrNzFsmbHQH+ppfLJxgUAUDFxinxQFj0/OriRAH5upqZVHGKAIEjCAAVJtypqXbmpEXrnOKAM4Id1Iye1W2Ta/tUtvbmR9xHyigCvbWu4bmyAKS8bd8qngVenODsTgCqhhIzkHFAFLy+w60bOKutHSeXxQBTCH0qzCu5OlOVOanhjzkUAQqnNXoFwBmoymDVqJDgelAFq36itzTsg+1Y1unzCtqzwqr1oA2UHAqV1LRECmQ4KZqzGARigDJkQqcGmkfLV66QBjjFQBRtI/lQBmSoRyDmq54OcVpSpjOD1qo8XcflQBWflcVQcYPNaTIaozr8/NAEO8elC8MKc0fNIFPvQBZk+aPNU2+90q/AuVxTLmAjtg9qAKfamGpCMcHrTSM/WgBpOBQPWlPPakANAFlGDrgdcVn3KlWNWFYo3B+tPmQSoCvWgDLkTctZ9zGVY9s1sBcZB4NVrqMZ5GRQBjbSTil8vjrVmSIgZHSkELYBb5R79aAKjA9AKlihIXc5wPTuam+VT8i8/3mFHJPzHNADl5OQABUinB4NRsD0A6U5FJI2/jQBbiXAz3q/L8tiSfSqUWE+9VqVg9i4PpQBzl9Jhi2eD2qpDMGcdM1JeE7iO1Z20pN6D1oA6OxbKspPPatJcLCFPXrWHpjF5VIOQDzW5JkjjpQBRkUK59+eKKnZC3NFAH0frMeUx1rw3xP4YGma9PdxIdl23mE44Vu4r6AvYfMwcVi6jpkNypSaNXT0IzQB4zptjNcMFiiZyP7orp9O8JyTSB71jGg/gXk12ttp1vaLtghSNfRRip2AUcUAZtvaQ2UAit4wiY5wOv1rD8R3kVpayFiN5BCj8K0te1OOwhJbl2B2qO9ecardyXs7STE89B6D0FAHOyoXY/zqwsYEeBUskY7YApyJxigCqYxShNuAandcH2pNtAEYXJ4qRUFOVamjiLMtAEKwb3wPzqaTEabV69KuSosMeR1qkFLHJoArhCc9zSsvHSrIj4pfLFAFIxnHApgj9RWgIgRTfJGeelAFER4qWGNi3SrYjAHSkC4IoAQReoqeNOKFXJzirKIMcUAS2yVoRRNgYqvbDGa0YT8lAGhaD92M9atxjBqnat2NXlGKAK16vAPSquMVp3CBo+2aoHGzP4UAU5QTVdhz0rQaMEcVVkXGaAKkjf3gKqSIGYkVfkUMMYqs0XPtQBVKc89KTYO1WwuKYwyM4oAWH5MccEUTfPj06CpUAKjANSeSB1NAGVLFgk4NQla2HhDAjORVOWIKeaAKWPajZxVhkAHWo5MDsaAKknFSWr4O0/dprkdlpoZgOOKAJrmDI3J071WeNWGGbH0q7byE/I5yKZcQbDuX7p7UAZ/lAdF/E81TkhJYnBzWoRUZjGc0AZjJjtg1HjBrQkhJzjFQeQQeQcUARhdw9Klij9O9TRx8Y4qzHGFyfQUAVplAXB4pbc5spFJ55plwxJzUluAbOUjrzQBz97GTj2rLuiwQ7RW0TuzuGO1VpIQqlsZA7e9AE3h0MInLHr+lbifNF6kVi6GcCQHjPIrWtHy5U9xQA9cAc0VVnkCvtJ6UUAfVtQzRAgnvU1Q3ThIjk0Ac1r2p22lr/pDfM33VAyTXIXni0tGVt4trnu/amfEe8R72CJSpkQEnHXnpXHoxbrQBdvrqS6Jklcu3v/AErMkBJJ6CrR5GKiKHOMcUAVCnNOjAU1LIoHApFHIoAY6ZPtTfLBPIq0ycUCMjnFAEKR84Aq7DEIl3N1p9tDkl2GAKWYlmwOgoArS5kzmoFTmriofTNJ5eDyMUAQLGc9OKeIxjnpUyrxxTtuKAIPLHpSbOvpVjb60hXB4oArsoHXGahIxVzZTWi4OaAKw3EDAqxFu6E0qR4FSRrzmgC1A2Dir8ZwoFUYl+YYq7EOlAF61zurTUcVlW5IYHtWtFyv4UAO25jNZsq4citVR2qjdJh+lAFUjIqrL97GKugVFIgPWgChJkZzURFWZ1ABqsSAOOaAI2B3dqaMc5qRm4JwKZuz1FAE0IGKmIyM5qO2Ix2qbpx2oAibgdarXKDrxVtgTwRVe6wBQBScDHaqsp6ippW5xVZ2zmgCFjSUpHOaMcUAHPrV22kDrh8E9BVM/pQvGCKALNxb/wAS1UKkHke1aFvPkhWHFTy26vgrzQBklPal8v5eRWgbbA4qJkIzxQBRaLaMg8VE8xAIFXmXjp1qhdR7VJHSgClM/bAxVuxP+iS8+tUJSDGeelXNL/49pcnjJoAxSGWUk/dJxUkwG3Bz9BSy/Pu7AE4pkXMZBOSOlAEmnQ7QzjtV6FtsiM3SoLRsHGMdqjuJCJMA/dNAC3RxO+c5zRUeoMRdMfXBooA+t6o6p9wfSiigDwvxexPiG8yScMAM/SqUfaiigCVetDfeNFFAEB70q0UUAWf4BSL1FFFAF48Q8VAO9FFACrSN3oooAB0ooooAQ0ooooAO9IaKKABacnWiigC3B1q1H1NFFAFqHpWtbfcH0oooAsJ1qpfdBRRQBT7CopOgoooApXHQ1VoooAa3T8aY1FFAEkH3qur0FFFADX+41UZTwaKKAM6YndVY9fxoooAa/SkHQUUUAKv3TTqKKAJIutatpyOaKKAH3PaoPSiigCnc8MMVVk5R8+lFFAGHMBkjHFX9O/49p/rRRQBl9j+NNHVfpRRQBMvHSq93/wAfB/CiigBuqH/Sf+AiiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain antero-posterior radiograph of the chest in a patient with rupture of the left hemidiaphragm following motor vehicle accident. The stomach is located in the chest (arrow A) and can be identified from the abnormal location of the nasogastric tube (arrow B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17457=[""].join("\n");
var outline_f17_3_17457=null;
var title_f17_3_17458="Hurthle cell lesion FNA";
var content_f17_3_17458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60286&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hurthle cell thyroid lesion: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fine needle aspirate of a thyroid nodule showing sheets of large polygonal Hurthle cells (also called oncocytes, Askanazy cells or oxyphil cells) with abundant oxyphilic cytoplasm. The nodule is benign if there is no evidence of vascular or capsular invasion after surgical excision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17458=[""].join("\n");
var outline_f17_3_17458=null;
var title_f17_3_17459="Neuromuscular disorders impairing gastric motor function";
var content_f17_3_17459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Neuromuscular disorders impairing gastric motor function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several common neurologic disorders can affect gastrointestinal motility by altering the parasympathetic or sympathetic supply to the gut.",
"    <div class=\"footnotes\">",
"     X: vagal nuceli; CNS: central nervous system; CVA: cerebrovascular accident; SCG: sympathetic chain ganglia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Camilleri M, Prather CM. In: Sleisenger and Fordtran's Gastrointestinal Disease, 6th ed, Feldman M, Scharschmidt BF, Sleisenger MH (Eds),&nbsp;WB Saunders, Philadelphia 1998. p.572.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17459=[""].join("\n");
var outline_f17_3_17459=null;
var title_f17_3_17460="Incomplete RBBB tutorial";
var content_f17_3_17460=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Incomplete right bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 134px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Delayed conduction through the right bundle branch does not affect the initial portion of the QRS complex (septal activation), but alters the terminal portion. There is an rsR' pattern in leads aVR and V1, and a qRs morphology in leads I and V6. The width of the QRS complex is only slightly prolonged, between 0.10 and 0.12 seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17460=[""].join("\n");
var outline_f17_3_17460=null;
var title_f17_3_17461="Chapter 8B: Regulation of the effective circulating volume";
var content_f17_3_17461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 8B: Regulation of the effective circulating volume",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17461/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/3/17461/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body responds to variations in the effective circulating volume in two steps: (1) the change is sensed by the volume receptors; and (2) these receptors then activate a series of effectors that restore normovolemia by varying vascular resistance, cardiac output, and renal Na+ and water excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VOLUME RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary volume receptors are in the cardiopulmonary circulation, the carotid sinuses and aortic arch, and the afferent glomerular arterioles in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although it is volume that is being regulated, it is difficult to conceive of receptors that sense total extracellular, plasma, or capillary volume. What is actually being sensed at most of the renal and extrarenal volume receptors is pressure (or stretch) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/3\">",
"     3",
"    </a>",
"    ]. This allows effective volume control, since pressure and volume are usually directly related. As an example, volume depletion induced by vomiting is sequentially associated with reductions in venous return to the heart, intracardiac filling pressures, cardiac output, and systemic blood pressure.",
"   </p>",
"   <p>",
"    In the kidney, the major volume receptors are the stretch receptors in the juxtaglomerular apparatus of the afferent arteriole and, to a lesser degree, the macula densa cells in the early distal tubule. These receptors affect volume balance by influencing the activity of the renin-angiotensin-aldosterone system and endothelin and nitric oxide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the extrarenal receptors (such as those in the atria and the carotid sinus) primarily govern the activity of the sympathetic nervous system and ANP [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Volume depletion, for example, can diminish both the intracardiac and systemic blood pressures, resulting in an increase in sympathetic tone and a reduction in the release of ANP, the consequences of which will be discussed below. These changes are reversed with volume expansion.",
"   </p>",
"   <p>",
"    The role of cardiopulmonary receptors has been demonstrated in humans by the response to immersion to the neck in warm water [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In this setting, the hydrostatic pressure of the water on the lower extremities results in the redistribution of intravascular fluid from the legs to the chest. The ensuing increase in central blood volume (and subsequently in cardiac output) is associated with a marked increase in Na+ and water excretion in an attempt to restore normovolemia (",
"    <a class=\"graphic graphic_figure graphicRef75930 \" href=\"UTD.htm?6/16/6414\">",
"     figure 1",
"    </a>",
"    ). Although aldosterone secretion is decreased in this setting, the natriuretic response shows a better temporal correlation with the associated increase in ANP release [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar natriuretic response to neck immersion can be demonstrated in many patients with cirrhosis and ascites who excrete little Na+ in the basal state (",
"    <a class=\"graphic graphic_figure graphicRef75930 \" href=\"UTD.htm?6/16/6414\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This observation supports the view that the reduced Na+ excretion in cirrhosis is due to effective volume depletion, even though these patients have, as described above, elevations in the plasma volume and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although multiple receptors are involved in the regulation of the effective circulating volume, no single receptor appears to be of primary importance. As examples, Na+ balance is generally well maintained in the presence of cardiac or renal denervation or the chronic administration of aldosterone (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/8-11\">",
"     8-11",
"    </a>",
"    ], indicating that, although these factors may be important in normal subjects, other receptors are capable of maintaining volume homeostasis. As an example, volume changes have direct mechanical effects on cardiac output and blood pressure, and the latter can influence NaCl and water excretion when other regulatory systems have failed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link&amp;anchor=H6#H6\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\", section on 'Pressure natriuresis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple effectors are involved in volume control, influencing both systemic hemodynamics and urinary Na+ excretion (",
"    <a class=\"graphic graphic_table graphicRef51061 \" href=\"UTD.htm?9/61/10203\">",
"     table 1",
"    </a>",
"    ). Since these regulatory systems (except for the sympathetic nervous system) have been discussed previously in Chaps. 3 and 6, their effects will only be briefly reviewed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathetic neural tone and the secretion of catecholamines (norepinephrine and epinephrine) from the adrenal medulla are reduced by volume expansion and enhanced by volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Thus, effective volume depletion, due to fluid losses or to reduced tissue perfusion in cirrhosis or heart failure, is associated with increased systemic and renal sympathetic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of sympathetic function in this setting is presumably related to an initial fall in effective cardiac output, due to decreased venous return, vasodilatation (as in cirrhosis), or to primary cardiac disease. From the formula relating pressure, output, and resistance,&dagger;",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Mean arterial pressure &nbsp; = &nbsp; cardiac output &nbsp;x &nbsp;systemic vascular resistance",
"   </p>",
"   <p>",
"    &dagger; The product of cardiac output and systemic vascular resistance actually equals the change in pressure across the circulation, i.e., mean arterial pressure minus mean venous pressure. However, only a small error results from ignoring the venous pressure, since it is so much lower (normal equals 1 to 7 mmHg) than the mean arterial pressure.",
"   </p>",
"   <p>",
"    The reduction in cardiac output lowers the systemic blood pressure. This decrease in pressure is sensed by the cardiac and arterial baroreceptors, resulting in a change in baroreceptor afferent discharge to the vasomotor centers in the brainstem [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. These centers then induce an increase in peripheral sympathetic tone, initiating a series of events that act to restore normal tissue perfusion (",
"    <a class=\"graphic graphic_algorithm graphicRef67477 \" href=\"UTD.htm?21/1/21534\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Venous constriction increases blood delivery to the heart, since about 70 percent of the vascular volume is normally contained within the venous system.",
"     </li>",
"     <li>",
"      Myocardial contractility and heart rate are increased which, in combination with the enhanced venous return, raises the cardiac output.",
"     </li>",
"     <li>",
"      Direct arteriolar constriction increases systemic vascular resistance, thereby elevating the systemic blood pressure toward normal.",
"     </li>",
"     <li>",
"      Renin secretion is enhanced, resulting in the generation of angiotensin II, which contributes to the systemic vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal tubular Na+ reabsorption is enhanced because of both a direct adrenergic effect and increases in angiotensin II and aldosterone secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/12,19,20\">",
"       12,19,20",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42947?source=see_link\">",
"       \"Chapter 6H: Catecholamines and the kidney\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cardiovascular changes are reversed by volume expansion, as sympathetic activity is reduced, thereby minimizing the elevations in cardiac output and blood pressure and facilitating the excretion of the excess Na+ [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of this regulatory system is illustrated in Figure 3 (",
"    <a class=\"graphic graphic_figure graphicRef62420 \" href=\"UTD.htm?14/61/15327\">",
"     figure 2",
"    </a>",
"    ). Although normal subjects easily tolerate the removal of 500 mL of blood (the equivalent of donating one unit of blood), patients with autonomic insufficiency can develop severe hypotension. These patients also have both postural hypotension, since they cannot compensate for the pooling of blood in the legs that occurs when one assumes the erect position, and an impaired ability to maximally conserve Na+, presumably due to removal of the adrenergic stimulus to tubular Na+ reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/12,21,22\">",
"     12,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiology of the renin-angiotensin system is discussed in detail in Chap. 2. Reviewed briefly, renin secretion is enhanced in hypovolemic disorders, resulting in the generation of angiotensin II, which has two major actions: it raises the blood pressure by arterial vasoconstriction, both directly and by enhancing the release and effect of norepinephrine; and it induces renal Na+ retention, both directly and by increasing the secretion of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. As with sympathetic blockade, inhibition of the renin-angiotensin system in hypovolemic subjects can lead to marked hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vasoconstriction induced by angiotensin II and norepinephrine in the presence of hypovolemia is compensatory in that it tends to maintain the systemic blood pressure; however, renal Na+ retention is usually required for the restoration of normovolemia. As an example, a decrease in volume due to fluid loss can be corrected only by the ingestion and subsequent retention of exogenous Na+ and water.",
"   </p>",
"   <p>",
"    The situation is different when effective volume depletion is due to heart failure or to cirrhosis with ascites. In this setting, the effect of the fluid retention is dependent upon the severity of the underlying disorder. This concept is illustrated in Figure 4 (",
"    <a class=\"graphic graphic_figure graphicRef52302 \" href=\"UTD.htm?11/49/12063\">",
"     figure 3",
"    </a>",
"    ), which depicts the response to decreasing venous return by partial constriction of the thoracic inferior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/25\">",
"     25",
"    </a>",
"    ]. There is an initial rapid decline in mean aortic pressure that is returned toward normal within one day, primarily by activation of the renin-angiotensin-aldosterone system. This is accompanied by a marked reduction in Na+ excretion, leading to a progressive increase in the plasma volume and the development of ascites due to an elevation in hepatic venous pressure. By day seven, however, the degree of volume expansion is sufficient to normalize venous return. As a result, a",
"    <strong>",
"     new steady state",
"    </strong>",
"    is achieved in which systemic hemodynamics are normal and the plasma renin activity and aldosterone level fall and urinary Na+ excretion rises toward the level of intake.",
"   </p>",
"   <p>",
"    However, it is not always possible to reach a new steady state. If the vena caval constriction is very severe, then marked Na+ retention and activation of the renin-angiotensin system persist, because fluid retention is unable to sufficiently enhance venous return. A similar sequence can occur in humans with heart failure. Patients who are clinically stable may have a normal blood pressure and a normal plasma renin activity, whereas patients with decompensated heart failure tend to be relatively hypotensive with high plasma renin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/27\">",
"     27",
"    </a>",
"    ]. Even those with a relatively normal plasma renin activity may still have increased activity of the",
"    <strong>",
"     intrarenal",
"    </strong>",
"    renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17461/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The continuation of this text is available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=see_link\">",
"     \"Chapter 8C: Regulation of renal Na+ excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/1\">",
"      Schrier RW. An odyssey into the milieu int&eacute;rieur: pondering the enigmas. J Am Soc Nephrol 1992; 2:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/2\">",
"      Skorecki KL, Brenner BM. Body fluid homeostasis in man. A contemporary overview. Am J Med 1981; 70:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/3\">",
"      Kimani JK. Elastin and mechanoreceptor mechanisms with special reference to the mammalian carotid sinus. Ciba Found Symp 1995; 192:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/4\">",
"      Epstein M. Cardiovascular and renal effects of head-out water immersion in man: application of the model in the assessment of volume homeostasis. Circ Res 1976; 39:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/5\">",
"      Epstein M, Loutzenhiser R, Friedland E, et al. Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans. J Clin Invest 1987; 79:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/6\">",
"      Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 1988; 319:1065,1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/7\">",
"      Epstein M, Pins DS, Schneider N, Levinson R. Determinants of deranged sodium and water homeostasis in decompensated cirrhosis. J Lab Clin Med 1976; 87:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/8\">",
"      Peterson TV, Jones CE. Renal responses of the cardiac-denervated nonhuman primate to blood volume expansion. Circ Res 1983; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/9\">",
"      Peterson TV, Chase NL, Gray DK. Renal effects of volume expansion in the renal-denervated nonhuman primate. Am J Physiol 1984; 247:H960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/10\">",
"      Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone \"escape\". Hypertension 1984; 6 (suppl I):I-183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/11\">",
"      Gonzalez-Campoy JM, Romero JC, Knox FG. Escape from the sodium-retaining effects of mineralocorticoids: role of ANF and intrarenal hormone systems. Kidney Int 1989; 35:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/12\">",
"      DiBona GF. Renal neural activity in hepatorenal syndrome. Kidney Int 1984; 25:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/13\">",
"      FRYE RL, BRAUNWALD E. Studies on Starling's law of the heart. I. The circulatory response to acute hypervolemia and its modification by ganglionic blockade. J Clin Invest 1960; 39:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/14\">",
"      FREIS ED, STANTON JR, FINNERTY FA Jr, et al. The collapse produced by venous congestion of the extremities or by venesection following certain hypotensive agents. J Clin Invest 1951; 30:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/15\">",
"      Henriksen JH, Bendtsen F, Gerbes AL, et al. Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992; 16:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/16\">",
"      P&eacute;rez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/17\">",
"      Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/18\">",
"      Gordon RD, K&uuml;chel O, Liddle GW, Island DP. Role of the sympathetic nervous system in regulating renin and aldosterone production in man. J Clin Invest 1967; 46:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/19\">",
"      Osborn JL, Holdaas H, Thames MD, DiBona GF. Renal adrenoceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog. Circ Res 1983; 53:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/20\">",
"      Gill JR Jr, Casper AG. Role of the sympathetic nervous system in the renal response to hemorrhage. J Clin Invest 1969; 48:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/21\">",
"      Wilcox CS, Puritz R, Lightman SL, et al. Plasma volume regulation in patients with progressive autonomic failure during changes in salt intake or posture. J Lab Clin Med 1984; 104:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/22\">",
"      GILL JR Jr, MASON DT, BARTTER FC. ADRENERGIC NERVOUS SYSTEM IN SODIUM METABOLISM: EFFECTS OF GUANETHIDINE AND SODIUM-RETAINING STEROIDS IN NORMAL MAN. J Clin Invest 1964; 43:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/23\">",
"      Cogan MG. Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension 1990; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/24\">",
"      Seidelin PH, McMurray JJ, Struthers AD. Mechanisms of the antinatriuretic action of physiological doses of angiotensin II in man. Clin Sci (Lond) 1989; 76:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/25\">",
"      Watkins L Jr, Burton JA, Haber E, et al. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 1976; 57:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/26\">",
"      Schroeder ET, Anderson GH, Goldman SH, Streeten DH. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 1976; 9:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/27\">",
"      Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17461/abstract/28\">",
"      Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90:1523.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7256 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17461=[""].join("\n");
var outline_f17_3_17461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VOLUME RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7256\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7256|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?21/1/21534\" title=\"algorithm 1\">",
"      Sympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7256|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/16/6414\" title=\"figure 1\">",
"      Response to neck immersion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/61/15327\" title=\"figure 2\">",
"      Autonomic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/49/12063\" title=\"figure 3\">",
"      Renin in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7256|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10203\" title=\"table 1\">",
"      Volume regulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/60/42947?source=related_link\">",
"      Chapter 6H: Catecholamines and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6744?source=related_link\">",
"      Chapter 8C: Regulation of renal Na+ excretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_3_17462="Abacavir and lamivudine: Pediatric drug information";
var content_f17_3_17462=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abacavir and lamivudine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"    see \"Abacavir and lamivudine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/61/38869?source=see_link\">",
"    see \"Abacavir and lamivudine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epzicom&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2519848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kivexa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F995401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F995425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"      see \"Abacavir and lamivudine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;16 years to &lt;18 years: Limited data available: Oral: 1 tablet daily (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;18 years of age and Adults: Oral: 1 tablet daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute: Use not recommended; use individual antiretroviral agents to reduce dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use is contraindicated; use individual antiretroviral agents to reduce dosage",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3338694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Epzicom&reg;: Abacavir 600 mg and lamivudine 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F128786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088592.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088592.pdf",
"     </a>",
"     , must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F995430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regards to meals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F995419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F995402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;18 years and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F128833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Postmarketing and/or case reports: Alopecia, anaphylaxis, anemia, aplastic anemia, breath sounds abnormal, CPK increased, erythema multiforme, fat redistribution, hepatic steatosis, hepatitis B exacerbation, hyperglycemia, hypersensitivity reaction, immune reconstitution syndrome, lactic acidosis, lymphadenopathy, muscle weakness, pancreatitis, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, splenomegaly, Stevens-Johnson syndrome, stomatitis, urticaria, weakness, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F995407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to abacavir, lamivudine, or any component; hepatic impairment.",
"     <b>",
"      Do not rechallenge",
"     </b>",
"     patients who have experienced hypersensitivity reactions to abacavir (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status); potentially fatal hypersensitivity reactions may occur.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4042702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). Resistance to abacavir develops relatively slowly, but cross resistance between abacavir and other nucleoside reverse transcriptase inhibitors (NRTIs) may occur; limited response may be seen in patients with HIV isolates containing multiple mutations conferring resistance to NRTIs or in patients with a prolonged prior NRTI exposure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including abacavir; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution;  time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use of abacavir has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials with abacavir therapy, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Do not administer Epzicom&reg; with abacavir- or lamivudine-containing products (eg, Epivir&reg;, Combivir&reg;, Trizivir&reg;, or Ziagen&reg;) or emtricitabine-containing products (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, or Truvada&reg;).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Abacavir  may cause mild hyperglycemia; more common in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F995408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and sometimes fatal hypersensitivity reactions to abacavir may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients testing positive for the presence of the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele are at a significantly increased risk for hypersensitivity reactions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Screening for",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele status is recommended prior to initiating therapy or reinitiating therapy in patients of unknown genotype status, including patients who previously tolerated therapy. Patients  who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele should have an abacavir allergy recorded in their medical record and should",
"     <b>",
"      not",
"     </b>",
"     receive abacavir. If a suspected abacavir hypersensitivity reaction occurs during therapy, regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status, abacavir should be discontinued immediately and permanently. Hypersensitivity reactions may also occur in patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele, but at a significantly lower rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Abacavir hypersensitivity is a multiorgan clinical syndrome",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Discontinue therapy immediately in patients who show signs or symptoms of 2 or more of the following: Fever, skin rash, respiratory symptoms (including cough, dyspnea, or pharyngitis), GI symptoms (including nausea, vomiting, diarrhea, or abdominal pain), and constitutional symptoms (including fatigue, malaise, or achiness). Carefully consider the diagnosis of hypersensitivity reaction in patients who present with acute onset respiratory symptoms, even if other diagnoses, such as bronchitis, flu-like illness, pharyngitis, or pneumonia, are possible. Permanently discontinue abacavir-containing medications if hypersensitivity reaction cannot be ruled out, even when other diagnoses are possible (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Skin rash may be maculopapular or urticarial, but can be variable in appearance; erythema multiforme has been reported; hypersensitivity reaction may occur without a rash. Other symptoms may include edema, lethargy, myolysis, paresthesia, shortness of breath, mouth ulcerations, conjunctivitis, lymphadenopathy, and abnormal findings on chest x-ray (ie, infiltrates that can be localized). Anaphylaxis, renal failure, hepatic failure, respiratory failure, ARDS, hypotension, and death may also occur in association with hypersensitivity reactions. Laboratory abnormalities include increases in liver function tests, elevated CPK or serum creatinine, and lymphopenia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Do not restart",
"     </b>",
"     abacavir, Epzicom&reg;, or any other abacavir-containing product after a hypersensitivity reaction occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; more severe symptoms can recur within hours and may include life-threatening hypotension and death. Fatal hypersensitivity reactions have occurred following the reintroduction of abacavir in patients whose therapy was interrupted for other reasons",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These patients had no identified history or had unrecognized symptoms of abacavir hypersensitivity. Reactions occurred within hours. In some cases, signs of a hypersensitivity reaction may have been previously present, but attributed to other medical conditions (acute onset respiratory diseases, gastroenteritis, or reactions to other medications). If abacavir, Epzicom&reg;, or any other abacavir-containing product is to be restarted following an interruption in therapy, the patient must first be evaluated for previously unsuspected symptoms of hypersensitivity.",
"     <b>",
"      Do not restart",
"     </b>",
"     abacavir, Epzicom&reg;, or any other abacavir-containing product if hypersensitivity is suspected or cannot be ruled out (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status). Hypersensitivity reactions occur in 5% to 8% of adult and pediatric patients (actual incidence varies by race/ethnicity); most hypersensitivity reactions occur within the first 6 weeks of therapy, but can occur at any time.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported in patients receiving nucleoside analogues",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue Epzicom&reg;  in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The major clinical toxicity of lamivudine in pediatric patients is pancreatitis; discontinue therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. HIV-infected patients who are coinfected with hepatitis B may experience severe acute exacerbations and clinical symptoms or laboratory evidence of hepatitis when a lamivudine-containing medication is discontinued",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most cases are self-limited, but fatalities have been reported; monitor patients closely for at least several months after discontinuation of abacavir and  lamivudine; initiation of antihepatitis B therapy may be required.",
"     <b>",
"      Note:",
"     </b>",
"     HIV-infected patients should be screened for hepatitis B infection prior to starting lamivudine therapy. Concomitant use of combination antiretroviral therapy with interferon alfa (with or without ribavirin) has resulted in hepatic decompensation (with some fatalities) in patients coinfected with HIV and HCV; monitor patients closely, especially for hepatic decompensation; consider discontinuation of abacavir and lamivudine if needed; consider dose reduction or discontinuation of interferon alfa, ribavirin, or both if clinical toxicities, including hepatic decompensation, worsen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Epzicom&reg; contains abacavir and lamivudine as a fixed-dose combination; do not use in patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute) who require lamivudine dosage adjustment or in patients with hepatic dysfunction. Abacavir is contraindicated in patients with moderate to severe hepatic dysfunction; patients with mild hepatic impairment require abacavir dosage reduction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3317866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4042703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the rate, but not the extent of absorption; in a single dose study, a high-fat meal did not change bioavailability or peak concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F128793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F128806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F995432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     genotype status prior to initiating therapy or resuming therapy in patients of unknown",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status (including patients previously tolerating therapy); signs and symptoms of abacavir hypersensitivity reaction (in all patients, but especially in those untested for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age)  at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, pancreatitis or lactic acidosis; serum creatine kinase.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F995421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F995423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One Epzicom&reg; tablet is bioequivalent, in the extent (AUC) of absorption and peak concentration, to two abacavir 300 mg tablets and two lamivudine 150 mg tablets; see individual agents",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F4042704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/61/38869?source=see_link\">",
"      see \"Abacavir and lamivudine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epzicom&reg; is not a cure for HIV. Take Epzicom&reg; every day as prescribed; do not change dose or discontinue without physician's advice. If Epzicom&reg; is stopped for any reason, notify physician before restarting therapy. If a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Avoid alcohol. Notify physician if persistent severe abdominal pain, nausea, or vomiting occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Epzicom&reg; contains abacavir (also called Ziagen&reg;). Abacavir may cause serious and sometimes fatal allergic (hypersensitivity) reactions. Read the Patient Medication Guide received with each prescription and refill of abacavir and lamivudine. Stop taking Epzicom&reg; and notify physician immediately if two or more of the following sets of symptoms occur: Fever, rash, GI symptoms (nausea, vomiting, diarrhea, or abdominal pain); flu-like symptoms (severe tiredness, achiness, or generally ill feeling), or respiratory symptoms (sore throat, shortness of breath, cough). If an allergic (hypersensitivity) reaction to Epzicom&reg; (or abacavir, Ziagen&reg;, or Trizivir&reg;) is experienced,",
"     <b>",
"      never",
"     </b>",
"     take Epzicom&reg;, abacavir, Ziagen&reg;, or Trizivir&reg; again. Taking an abacavir-containing medication after having an allergic reaction may result in life-threatening symptoms, including very low blood pressure or death within hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including abacavir and lamivudine) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Before starting Epzicom&reg;, review medical conditions, including any kidney, heart, or liver problems (including hepatitis B infection), smoking status, diabetes, high cholesterol, or high blood pressure with physician. Do not take Epzicom&reg; with abacavir- or lamivudine-containing products (eg, Epivir&reg;, Combivir&reg;, Trizivir&reg;, or Ziagen&reg;) or emtricitabine-containing products (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, or Truvada&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F995436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The development of the abacavir hypersensitivity reaction has been associated with certain HLA genotypes (eg,",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     ,",
"     <i>",
"      HLA-DR7",
"     </i>",
"     ,",
"     <i>",
"      HLA-DQ3",
"     </i>",
"     ) which may help predict which patients are at risk for developing the abacavir hypersensitivity reaction (Hetherington, 2002; Lucas, 2007; Mallal, 2002). Patients who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele should have an abacavir allergy recorded in their medical record and should",
"     <b>",
"      not",
"     </b>",
"     receive abacavir. All patients who receive abacavir (and their caregivers) should be educated about the risk of abacavir hypersensitivity reactions (including patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele, as the risk for the reaction is not completely eliminated). Approximately 4% of patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele will experience a clinically suspected abacavir hypersensitivity reaction compared to 61% of those who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The prevalence of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     in the United States has been estimated to be 8% in Caucasians, 2.5% in African-Americans, 2% in Hispanics, &lt;1% in Asians; in the sub-Saharan Africa it is 1%. Pretherapy identification of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     -positive patients and subsequent avoidance of abacavir therapy in these patients has been shown to significantly reduce the occurrence of abacavir-associated hypersensitivity reactions. A skin patch test is in development for clinical screening purposes; however, only PCR-mediated genotyping methods are currently in clinical practice use for documentation of this susceptibility marker. A familial predisposition to the abacavir hypersensitivity reaction has been reported; use abacavir with great caution in children of parents who experience a hypersensitivity reaction to abacavir (Peyri&eacute;re, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reverse transcriptase mutations of K65R, L74V, Y115F, and M184V have been associated with abacavir resistance; at least 2-3 mutations are needed to decrease HIV susceptibility by 10-fold. The presence of a multiple number of these abacavir resistance-associated mutations, may confer cross-resistance for other nucleoside or nucleotide reverse transcriptase inhibitors (eg, didanosine, emtricitabine, lamivudine, zalcitabine, or tenofovir). A progressive decrease in abacavir susceptibility is associated with an increasing number of thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F, K219E/R/H/Q/N).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A high rate of early virologic failure in therapy-naive adult HIV patients has been observed with the once-daily three-drug combination therapy of abacavir, lamivudine, and tenofovir; this antiretroviral regimen is currently",
"     <b>",
"      not",
"     </b>",
"     recommended; any patient currently receiving this regimen should be closely monitored for virologic failure and considered for treatment modification",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHA Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hetherington S, Hughes AR, Mosteller M, et al, \"Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9312):1121-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/3/17462/abstract-text/ 11943262 /pubmed\" id=\" 11943262 \" target=\"_blank\">",
"        11943262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas A, Nolan D, and Mallal S, \"HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2007, 59(4):591-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/3/17462/abstract-text/17317695/pubmed\" id=\"17317695\" target=\"_blank\">",
"        17317695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mallal S, Nolan D, Witt C, et al, \"Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9308):727-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/3/17462/abstract-text/11888582/pubmed\" id=\"11888582\" target=\"_blank\">",
"        11888582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peyri&eacute;re H, Nicolas J, Siffert M, et al, \"Hypersensitivity Related to Abacavir in Two Members of a Family,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(10):1291-2.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12684 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-850F4342A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17462=[""].join("\n");
var outline_f17_3_17462=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708583\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2519848\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995401\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995425\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3338694\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128786\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874272\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995430\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995419\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995402\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128833\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995407\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4042702\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995408\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298625\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3317866\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4042703\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128793\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128806\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995432\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995421\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995423\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4042704\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F995436\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12684\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12684|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=related_link\">",
"      Abacavir and lamivudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/61/38869?source=related_link\">",
"      Abacavir and lamivudine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_3_17463="WPW radiofrequency ablation";
var content_f17_3_17463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Radiofrequency ablation for WPW syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surface ECG and intracardiac electrograms from a patient with Wolff-Parkinson-White syndrome (WPW) and a right lateral accessory pathway are simultaneously recorded. The patient is initially being paced from the high right atrium (HRA) at a cycle length of 500 msec to maximize preexcitation. The accessory pathway is localized to an area of the tricuspid annulus (Ta) and radiofrequency (RF) current is delivered via a deflectable tip ablation catheter. Preexcitation disappears (*) within 1.2 seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17463=[""].join("\n");
var outline_f17_3_17463=null;
var title_f17_3_17464="Unipolar depression in adults: Anxiolytics";
var content_f17_3_17464=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults: Anxiolytics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17464/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17464/contributors\">",
"     Andrew Goddard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17464/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17464/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17464/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17464/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/3/17464/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H30535202\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar major depression that includes high levels of anxiety is called anxious depression; a study of 2876 patients with major depression found that anxious features were present in more than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/1\">",
"     1",
"    </a>",
"    ]. These symptoms may take the form of worrying, rumination, health anxieties, and panic attacks. In addition, psychomotor agitation (eg, pacing and handwringing) may be considered an &ldquo;anxiety equivalent.&rdquo; Anxiety symptoms that are part of a depressive syndrome may be difficult to distinguish from anxiety disorders that are comorbid with depressive disorders; these comorbid disorders are discussed separately.",
"   </p>",
"   <p>",
"    The clinical significance of unipolar major depression with anxiety symptoms varies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxious depression may represent a depressive subtype that is more difficult to treat [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anxiety may be a prodromal or residual feature of depressive episodes (eg, postpartum depression often starts with increased anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/4\">",
"       4",
"      </a>",
"      ]) &nbsp;",
"     </li>",
"     <li>",
"      Anxiety may represent a response to impairment caused by the depressive syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute treatment of unipolar major depression with antidepressants is less effective in patients with higher levels of baseline anxiety than patients with lower levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. However, adjunctive anxiolytics can improve outcomes in anxious depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. In addition, insomnia that is part of the depressive syndrome often responds to anxiolytic (hypnotic) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the use of anxiolytics to treat unipolar major depression, including their indications, contraindications, administration, and efficacy. Choosing a medication regimen for the initial treatment of depression and for treatment resistant depression is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30535209\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for augmenting antidepressants with anxiolytics to treat unipolar major depression include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of anxiety, such as ruminative thoughts, worrying, health anxieties, excessive fears, and panic attacks. Major depression that includes high levels of anxiety is often referred to as &ldquo;anxious depression,&rdquo; and severe anxiety can increase the risk of suicide attempts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Moderate to severe insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psychomotor agitation (eg, pacing and handwringing) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Excessive activation (jitteriness) induced by antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and tricyclics [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The need to accelerate improvement in patients with moderate to severe depression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Treatment resistant depression (eg, nonresponse to at least two separate, adequate antidepressant trials) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The short term goals of coadministering anxiolytics with antidepressants are rapid anxiolysis, control of insomnia and agitation, and limiting antidepressant side effects. The longer term aim is remission of the depressive syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87788652\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In treating depressive syndromes, the following comorbidities are contraindications to augmenting antidepressants with anxiolytics, especially benzodiazepines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chronic posttraumatic stress disorder (PTSD)",
"      </strong>",
"      &ndash; There is no compelling evidence that benzodiazepines are effective for the core PTSD symptoms in this clinical context [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/13\">",
"       13",
"      </a>",
"      ]. In some patients, there is a risk of worsening PTSD symptoms such as hyperarousal and irritability. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Severe antisocial or borderline personality disorder",
"      </strong>",
"      &ndash; Long term administration of benzodiazepines is likely to worsen impulsivity in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/14\">",
"       14",
"      </a>",
"      ]. In addition, patients with these severe personality disorders are more prone to benzodiazepine dependence, and are more likely to engage in drug diversion.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate to severe substance use disorders antedating onset of the depressive syndrome",
"      </strong>",
"      &ndash; Patients whose history suggests a long-standing primary substance disorder are at higher risk for becoming dependent upon benzodiazepines [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Mild cognitive impairment or dementia",
"      </strong>",
"      &ndash; Most anxiolytics should be used with caution in dementia patients. However, we avoid long-term administration of benzodiazepines in this context, due to their sedative and amnestic properties, and risk of exacerbating cognitive impairments [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       General medical conditions such as severe myopathic disorders (eg, myasthenia gravis) and chronic respiratory diseases (eg, severe chronic obstructive pulmonary disease)",
"      </strong>",
"      &ndash; The muscle relaxant properties of anxiolytics, especially benzodiazepines, are likely to exacerbate these diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90524849\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10011920\">",
"    <span class=\"h2\">",
"     Patient assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation of patients with a possible diagnosis of unipolar major depression with anxiety includes a psychiatric history and mental status examination, with emphasis upon depressive and anxiety symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. The clinician should also obtain a general medical history, physical examination, and laboratory tests that are guided by the history and examination. Unipolar major depression is generally diagnosed according to the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessment of major depression can be facilitated by using the Patient Health Questionnaire - 9 Item (PHQ-9) (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 2",
"    </a>",
"    ), which is a nine item self-report instrument that screens for episodes of major depression, provides a diagnosis, has good psychometric properties, is in the public domain, and can be filled out by patients prior to the appointment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/24\">",
"     24",
"    </a>",
"    ]. An alternative is the two item Patient Health Questionnaire, which screens for depression but does not provide a diagnosis; patients who screen positive must be interviewed by the clinician to establish the diagnosis of major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/25\">",
"     25",
"    </a>",
"    ]. Additional information about diagnosing major depression and the PHQ-9 is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Major depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial assessment of anxiety symptoms (eg, excessive fears and worrying) can be facilitated with the seven item self-report scale for generalized anxiety disorder (GAD-7), which is in the public domain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/26\">",
"     26",
"    </a>",
"    ]. An alternative self report questionnaire is the Beck Anxiety Inventory, which consists of 21 items and focuses upon somatic symptoms, but is copyrighted and must be purchased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In addition, the 14 item Hamilton Anxiety Rating Scale assesses global anxiety, including psychic (cognitive) and somatic symptoms, and is in the public domain; however, this is a clinician administered instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following the initial evaluation, the effectiveness of treatment can be monitored with the PHQ-9 and GAD-7. A reasonable alternative is to use self-report visual analog scales; as an example, one Likert response item for level of depression and another for level of anxiety, each ranging from 0 (none) to 10 (extreme).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5087207\">",
"    <span class=\"h2\">",
"     When to start the anxiolytic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In treating unipolar major depression with an adjunctive anxiolytic, the point at which the drug is added depends upon the severity of the depressive syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      &ndash; For severe depression that includes anxiety",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insomnia, we typically start the anxiolytic at the same time as the antidepressant or soon thereafter (eg, within one to two weeks)",
"     </li>",
"     <li>",
"      <strong>",
"       Mild to moderate",
"      </strong>",
"      &ndash; For mild to moderate depression, we typically use a stepped care approach and start the anxiolytic later [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/31\">",
"       31",
"      </a>",
"      ]. The antidepressant is titrated up and then administered for a sufficient period (eg, four to eight weeks) to evaluate its efficacy as monotherapy. If anxiety",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insomnia persist, we then add the anxiolytic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10011853\">",
"    <span class=\"h2\">",
"     Duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon randomized trials, we suggest that clinicians coadminister the anxiolytic and the antidepressant for four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/3,32-34\">",
"     3,32-34",
"    </a>",
"    ]. There is little evidence that longer treatment is beneficial. When treatment with the anxiolytic is completed, the drug is tapered for two to four weeks prior to discontinuation. Information about discontinuing benzodiazepines is discussed elsewhere in this topic (see",
"    <a class=\"local\" href=\"#H30535216\">",
"     'Benzodiazepines'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10011913\">",
"    <span class=\"h1\">",
"     SPECIFIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific anxiolytic drugs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Benzodiazepines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonbenzodiazepine hypnotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       eszopiclone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Second-generation antipsychotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"       Pindolol",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       Buspirone",
"      </a>",
"     </li>",
"     <li>",
"      Other agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       riluzole",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30535216\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression, adding a benzodiazepine to an antidepressant can improve anxiety, insomnia and other symptoms of depression, and treatment adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/3,35-37\">",
"     3,35-37",
"    </a>",
"    ]. A meta-analysis of 10 randomized trials that compared adjunctive benzodiazepines with placebo in 731 depressed patients who received antidepressants found that at four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severity of depression was less with a benzodiazepine plus an antidepressant than antidepressant monotherapy; heterogeneity across trials was moderate to large. (The difference in depressive symptoms between the two treatment groups was greatest after one week and not demonstrable beyond six to eight weeks.)",
"     </li>",
"     <li>",
"      Response (improvement from baseline on the depression rating scale &ge;50 percent) occurred in more patients who received combination treatment than monotherapy (50 versus 38 percent); heterogeneity was small to moderate.",
"     </li>",
"     <li>",
"      Discontinuation of treatment due to adverse effects occurred in fewer patients who received adjunctive benzodiazepines than placebo (7 versus 13 percent); there was little to no heterogeneity across studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the benefits of adding a benzodiazepine must be balanced against potential harms that include tolerance (diminished effect over time), physiologic dependence, sedation, amnestic effects, impaired psychomotor speed, and increased accidents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/16,32,38\">",
"     16,32,38",
"    </a>",
"    ]. Benzodiazepines should be used cautiously or avoided in patients with a history of alcohol or substance abuse, or a history of problematic adherence to antidepressants; both groups may want to stop the antidepressant and continue only the benzodiazepine due to the benzodiazepine&rsquo;s more rapid clinical effect.",
"   </p>",
"   <p>",
"    If a benzodiazepine is indicated during treatment of unipolar major depression with an antidepressant, we generally start",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    at a dose of 0.5 mg at bedtime and titrate up over one to two weeks to a maximum dose of 2 mg per day, given at bedtime or divided in two daily doses. Although each of the benzodiazepines can be prescribed adjunctively with an antidepressant to treat unipolar depression, we prefer high potency, intermediate half-life agents (eg, clonazepam or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ). Compared with low potency, longer half-life drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ), high potency, intermediate half-life agents generally have simpler metabolisms with fewer active metabolites, and may thus have a lower risk of sedation and psychomotor problems such as falls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, clonazepam has been frequently studied for augmentation of antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/3,35,36\">",
"     3,35,36",
"    </a>",
"    ]. Information about the pharmacology of benzodiazepines, including doses, comparative potency, metabolism, and half-life is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef65653 \" href=\"UTD.htm?39/16/40205\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Based upon our clinical experience, patients should avoid using benzodiazepines on an as needed basis (PRN administration) because this approach is often not effective; fluctuating serum concentrations, especially with short acting drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    ), can increase the risk of minor withdrawal reactions and reinforce psychological dependence. In addition, as needed dosing may interfere with cognitive-behavioral therapy (CBT), by promoting rescue medication as a coping strategy that competes with the coping skills taught in CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benzodiazepines should be tapered over two to four weeks prior to discontinuation; tapering over a period less than two weeks may lead to rebound symptoms of depression and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/35,41\">",
"     35,41",
"    </a>",
"    ], and abrupt discontinuation can cause seizures. For patients who have been on a benzodiazepine for more than six months, we typically decrease the total daily dose by 10 percent every week until discontinuation. The benzodiazepine withdrawal syndrome is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link&amp;anchor=H11#H11\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\", section on 'Withdrawal'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10010939\">",
"    <span class=\"h3\">",
"     Alprazolam monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is strong evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    monotherapy is efficacious for treating unipolar depression, we rarely use this approach because of problems with abuse and dependency, particularly at higher doses (eg, &gt;2 mg per day).",
"   </p>",
"   <p>",
"    A systematic review of randomized trials that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    with placebo in patients with unipolar major depression reported the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of seven heterogeneous trials compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      with placebo in 771 patients who were treated for six weeks; the mean daily doses of alprazolam ranged from 2.1 to 3.7 mg and maximum daily doses ranged from 4.5 to 6 mg. Improvement of depressive symptoms was significantly greater with alprazolam than placebo.",
"     </li>",
"     <li>",
"      A separate analysis of 3 homogeneous trials (312 patients) found that response (improvement from baseline on the depression rating scale &ge;50 percent) occurred in more patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      than placebo (53 versus 22 percent)",
"     </li>",
"     <li>",
"      A third analysis of 17 trials (1636 patients) compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      with tricyclic antidepressants and found that improvement of symptoms was comparable; heterogeneity across studies was moderate to high. Alprazolam has not been directly compared with selective serotonin reuptake inhibitors (SSRIs). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30535230\">",
"    <span class=\"h2\">",
"     Nonbenzodiazepine hypnotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression that includes insomnia, adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    to an antidepressant is efficacious for treating insomnia, but it is not clear if these adjunctive drugs help resolve other core depressive symptoms. Evidence for the efficacy of these nonbenzodiazepine sedatives includes the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An eight week randomized trial compared adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      extended release (12.5 mg at bedtime) with placebo in 380 patients with unipolar major depression that included insomnia; all patients received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      (10 mg per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/43\">",
"       43",
"      </a>",
"      ]. Improvement of insomnia was greater in patients who received zolpidem than placebo; however, improvement of other depressive symptoms was comparable for both groups. Discontinuation of treatment due to adverse effects occurred in more patients who received adjunctive zolpidem than placebo (8 versus 4 percent).",
"     </li>",
"     <li>",
"      An eight week randomized trial compared adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       eszopiclone",
"      </a>",
"      (3 mg at bedtime) with placebo in 545 patients with unipolar major depression that included insomnia; all patients received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      20 to 40 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/8\">",
"       8",
"      </a>",
"      ]. Insomnia improved more with eszopiclone than placebo, and improvement of other depressive symptoms was superior with eszopiclone. Discontinuation of treatment due to adverse effects was comparable in patients who received adjunctive eszopiclone or placebo (6 and 8 percent). Among the subgroup of patients with anxious depression (major depression that includes high levels of anxiety), insomnia and other depressive symptoms improved more with adjunctive eszopiclone than placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abrupt discontinuation of the hypnotics in these two trials did not result in appreciable rebound insomnia, which is a significant advantage over benzodiazepines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30535251\">",
"    <span class=\"h2\">",
"     Second-generation antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    are each beneficial for anxious depression (major depression that includes high levels of anxiety). Evidence for the efficacy of these &ldquo;major tranquilizers&rdquo; includes the following studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pooled analysis of two eight-week randomized trials compared the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      extended release monotherapy with placebo in patients with unipolar major depression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/34\">",
"       34",
"      </a>",
"      ]. In the subgroup of 403 patients with anxious depression, response (improvement from baseline on the depression rating scale &ge;50 percent) occurred in more patients who received quetiapine 150 mg or 300 mg per day than placebo (50 and 47 versus 32 percent). This was consistent with the finding that quetiapine was superior to placebo in nonanxious depression. Side effects of quetiapine include dry mouth, sedation, and weight gain.",
"     </li>",
"     <li>",
"      A pooled analysis of two six-week randomized trials compared the efficacy of adjunctive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      (2 to 20 mg per day) with placebo in patients with unipolar major depression who were unresponsive to antidepressant monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/33\">",
"       33",
"      </a>",
"      ]. In the subgroup of 435 patients with anxious depression, remission occurred in more patients who received aripiprazole than placebo (25 versus 16 percent). This was consistent with the finding that adjunctive aripiprazole was superior to placebo in nonanxious depression. Side effects associated with aripiprazole in patients with anxious depression included akathisia, fatigue insomnia, blurred vision, and constipation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about adjunctive treatment with second-generation antipsychotics in patients with unipolar major depression who do not respond to antidepressant monotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=see_link\">",
"     \"Unipolar depression in adults: Treatment with second-generation antipsychotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172922575\">",
"    <span class=\"h2\">",
"     Pindolol",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unipolar major depression, adding the beta blocker",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    (eg, 5 mg three times per day) to a selective serotonin reuptake inhibitor (SSRI) can improve depressive symptoms and may accelerate clinical response via blockade of the 5-HT1A autoreceptor. A meta-analysis of 12 randomized trials compared pindolol plus an SSRI with placebo plus an SSRI in 889 patients with unipolar major depression and no history of treatment resistance. Response (improvement from baseline on the depression rating scale &ge;50 percent) at two weeks occurred in more patients who received adjunctive pindolol than placebo (37 versus 21 percent); however, heterogeneity across trials was high [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/46\">",
"     46",
"    </a>",
"    ]. In a second analysis, response at four to six weeks occurred in more patients who received adjunctive pindolol than placebo (74 versus 67 percent), and there was little to no heterogeneity. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172922236\">",
"    <span class=\"h2\">",
"     Buspirone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Augmentation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    does not appear to help patients with anxious depression (major depression that includes high levels of anxiety). The effectiveness of buspirone was evaluated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which compared buspirone (mean dose 41 mg per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    sustained release (mean dose 268 mg per day) plus citalopram in 565 patients with unipolar major depression who were initially unresponsive to citalopram monotherapy. Treatment was randomly assigned and administered on an open label basis, assessment of outcome was blinded, and concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    and benzodiazepines was permitted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/47\">",
"     47",
"    </a>",
"    ]. Among patients with anxious depression who received adjunctive buspirone, remission occurred in only 9 percent, compared to 39 percent of patients with nonanxious depression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90524902\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       Doxepin",
"      </a>",
"      &ndash; Randomized trials have demonstrated that the tricyclic antidepressant doxepin (3 or 6 mg at bedtime), which antagonizes the H1 receptor, is efficacious for insomnia in patients who are not depressed (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of insomnia\", section on 'Antidepressants'",
"      </a>",
"      ). The drug may also be useful for insomnia associated with depression, but this has not been studied in a randomized trial.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/31/22004?source=see_link\">",
"       Riluzole",
"      </a>",
"      &ndash; A prospective observational study of 10 patients with unipolar major depression and anxiety found that augmentation of the antidepressant regimen with riluzole (a glutamate receptor antagonist that is used to treat amyotrophic lateral sclerosis) reduced symptoms of depression and anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?17/3/17464/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30535294\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unipolar major depression often includes symptoms of anxiety such as worrying or rumination. Anxiety symptoms that are part of a depressive syndrome are distinguished from anxiety disorders that are comorbid with depressive disorders. (See",
"      <a class=\"local\" href=\"#H30535202\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for augmenting antidepressants with anxiolytics to treat unipolar major depression include symptoms of anxiety, moderate to severe insomnia, psychomotor agitation, excessive activation induced by antidepressants, the need to accelerate improvement in patients with moderate to severe depression, and treatment resistant depression. (See",
"      <a class=\"local\" href=\"#H30535209\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contraindications to augmenting antidepressants with anxiolytics (especially benzodiazepines) to treat depression include several comorbidities, such as chronic posttraumatic stress disorder, severe antisocial or borderline personality disorder, moderate to severe substance use disorders antedating onset of the depressive syndrome, mild cognitive impairment or dementia, and general medical conditions such as severe myopathic disorders and chronic respiratory disease. (See",
"      <a class=\"local\" href=\"#H87788652\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depressive symptoms can be assessed with the self report Patient Health Questionnaire - 9 Item (PHQ-9) (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"       table 2",
"      </a>",
"      ), and anxiety symptoms with the self report scale for generalized anxiety disorder (GAD-7). A reasonable alternative is to use self-report visual analog scales. (See",
"      <a class=\"local\" href=\"#H10011920\">",
"       'Patient assessment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"       \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In using an adjunctive anxiolytic to treat severe unipolar major depression that includes anxiety",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insomnia, we typically start the anxiolytic at the same time as the antidepressant. For mild to moderate depression, we generally use a stepped care approach, in which the antidepressant is titrated up and administered for a sufficient period to evaluate its efficacy as monotherapy; if anxiety",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insomnia persist, we then add the anxiolytic. (See",
"      <a class=\"local\" href=\"#H5087207\">",
"       'When to start the anxiolytic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally coadminister the anxiolytic and the antidepressant for four to six weeks, and then taper the anxiolytic for two to four weeks prior to discontinuation. However, longer taper schedules may be necessary for benzodiazepines. (See",
"      <a class=\"local\" href=\"#H10011853\">",
"       'Duration of treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30535216\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar major depression, prescribing a benzodiazepine (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      0.5 to 2 mg per day at bedtime or divided in two daily doses) plus an antidepressant can improve symptoms of anxiety and depression, and also improve treatment adherence. However, the potential harms of adding a benzodiazepine include tolerance (diminished effect over time), physiologic dependence, sedation, amnestic effects, impaired psychomotor speed, and increased accidents. (See",
"      <a class=\"local\" href=\"#H30535216\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar major depression that includes insomnia, adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       eszopiclone",
"      </a>",
"      (3 mg at bedtime) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      (12.5 mg at bedtime) to an antidepressant is efficacious for treating insomnia, but it is not clear if these adjunctive drugs help resolve other core depressive symptoms. Abrupt discontinuation of these nonbenzodiazepine hypnotics does not result in appreciable rebound insomnia, which is a significant advantage over benzodiazepines. (See",
"      <a class=\"local\" href=\"#H30535230\">",
"       'Nonbenzodiazepine hypnotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      (150 mg or 300 mg per day) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      (2 to 20 mg per day) are each beneficial for anxious depression (major depression that includes high levels of anxiety). (See",
"      <a class=\"local\" href=\"#H30535251\">",
"       'Second-generation antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unipolar major depression who are treated with an antidepressant, adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"       pindolol",
"      </a>",
"      (eg, 5 mg three times per day) can accelerate or improve response to the antidepressant. (See",
"      <a class=\"local\" href=\"#H172922575\">",
"       'Pindolol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Augmentation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      (eg, 45 mg per day in two divided doses) may possibly benefit depressed patients who do not respond to antidepressant monotherapy, but does not appear to help patients with anxious depression. (See",
"      <a class=\"local\" href=\"#H172922236\">",
"       'Buspirone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/1\">",
"      Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/2\">",
"      Stewart JW, McGrath PJ, Fava M, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2010; 13:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/3\">",
"      Papakostas GI, Clain A, Ameral VE, et al. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol 2010; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/4\">",
"      Tuohy A, McVey C. Subscales measuring symptoms of non-specific depression, anhedonia, and anxiety in the Edinburgh Postnatal Depression Scale. Br J Clin Psychol 2008; 47:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/5\">",
"      Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007; 164:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/6\">",
"      Kim JM, Kim SW, Stewart R, et al. Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol 2011; 26:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/7\">",
"      Londborg PD, Smith WT, Glaudin V, Painter JR. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. J Affect Disord 2000; 61:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/8\">",
"      Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/9\">",
"      Katz C, Yaseen ZS, Mojtabai R, et al. Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry 2011; 72:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/10\">",
"      Richey SM, Krystal AD. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011; 17:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/11\">",
"      Allen MH, Currier GW, Hughes DH, et al. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/12\">",
"      Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 2009; 194:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/13\">",
"      Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev 2012; 49:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/14\">",
"      Pascual JC, Mart&iacute;n-Blanco A, Soler J, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol 2010; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/15\">",
"      Manthey L, Lohbeck M, Giltay EJ, et al. Correlates of benzodiazepine dependence in the Netherlands Study of Depression and Anxiety. Addiction 2012; 107:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/16\">",
"      Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/17\">",
"      Haroutiunian S, Lecht S, Zur AA, et al. The challenge of pain management in patients with myasthenia gravis. J Pain Palliat Care Pharmacother 2009; 23:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/18\">",
"      George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs 2003; 63:379.",
"     </a>",
"    </li>",
"    <li>",
"     Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.",
"    </li>",
"    <li>",
"     Rothschild AJ. Clinical Manual for Diagnosis and Treatment of Psychotic Depression, American Psychiatric Publishing, Inc., Washington, DC 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/21\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/24\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/25\">",
"      Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/26\">",
"      Spitzer RL, Kroenke K, Williams JB, L&ouml;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/27\">",
"      Steer RA, Ranieri WF, Beck AT, Clark DA. Further evidence for the validity of the Beck Anxiety Inventory with psychiatric outpatients. J Anxiety Disord 1993; 7:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/28\">",
"      Muntingh AD, van der Feltz-Cornelis CM, van Marwijk HW, et al. Is the Beck Anxiety Inventory a good tool to assess the severity of anxiety? A primary care study in the Netherlands Study of Depression and Anxiety (NESDA). BMC Fam Pract 2011; 12:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/29\">",
"      HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     Shear MK, Brown C, Clark DB. Anxiety disorders measures. In: Handbook of Psychiatric Measures, Second Edition, Rush Jr AJ, First MB, Blacker D.  (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.529.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/31\">",
"      Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 2005; 66:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/32\">",
"      Furukawa TA, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2001; :CD001026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/33\">",
"      Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008; 69:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/34\">",
"      Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety 2012; 29:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/35\">",
"      Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry 1998; 155:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/36\">",
"      Smith WT, Londborg PD, Glaudin V, et al. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord 2002; 70:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/37\">",
"      Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 2001; 65:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/38\">",
"      Chang CM, Wu EC, Chen CY, et al. Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study. Br J Clin Pharmacol 2013; 75:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/39\">",
"      Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011; 34:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/40\">",
"      Westra HA, Stewart SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anxiety Disord 2002; 16:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/41\">",
"      Feet PO, Larsen S, Lillevold PE, Robak OH. Withdrawal reactions to diazepam in combined imipramine/diazepam treatment of primary nonagitated depressed outpatients. Acta Psychiatr Scand 1988; 78:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/42\">",
"      van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev 2012; 7:CD007139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/43\">",
"      Fava M, Asnis GM, Shrivastava RK, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry 2011; 72:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/44\">",
"      Fava M, Schaefer K, Huang H, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011; 72:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/45\">",
"      Dannlowski U, Baune BT, B&ouml;ckermann I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol 2008; 23:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/46\">",
"      Portella MJ, de Diego-Adeli&ntilde;o J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011; 72:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/47\">",
"      Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17464/abstract/48\">",
"      Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61:822.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14670 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17464=[""].join("\n");
var outline_f17_3_17464=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30535294\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30535202\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30535209\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87788652\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90524849\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10011920\">",
"      Patient assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5087207\">",
"      When to start the anxiolytic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10011853\">",
"      Duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10011913\">",
"      SPECIFIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30535216\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10010939\">",
"      - Alprazolam monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30535230\">",
"      Nonbenzodiazepine hypnotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30535251\">",
"      Second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172922575\">",
"      Pindolol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172922236\">",
"      Buspirone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H90524902\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30535294\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14670\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14670|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 2\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/16/40205\" title=\"table 3\">",
"      Pharmacology benzodiazepines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31993?source=related_link\">",
"      Unipolar depression in adults: Treatment with second-generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_3_17465="Variants of uterine leiomyomas (fibroids)";
var content_f17_3_17465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Variants of uterine leiomyomas (fibroids)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Elizabeth A Stewart, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Bradley J Quade, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/3/17465/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/3/17465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20798632\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign uterine leiomyomas (fibroids) are the most common pelvic tumor in women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Rarely, women with a uterine mass presumed to be a leiomyoma are found to have a uterine sarcoma or a leiomyoma variant. There are a number of leiomyoma variants in which the smooth muscle tumor manifests one histologic facet of malignancy, yet lacks all others. Other variants are defined by their quasi-malignant capacity to metastasize while remaining histologically and clinically benign. Finally, some smooth muscle tumor variants cannot be definitely classified, and consequently are deemed to have an uncertain malignant potential.",
"   </p>",
"   <p>",
"    Histologically and biologically defined variants of uterine leiomyomas are reviewed here. The diagnosis and management of ordinary uterine leiomyomas, as well as approaches to differentiating leiomyomas from uterine sarcoma, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338813\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several rare syndromes with leiomyomas or leiomyoma-like lesions that require differentiation from ordinary uterine leiomyomas. The classification of these variants continues to evolve as information about their pathophysiology is gained. The currently used categories are descriptive in nature and are only beginning to be characterized in molecular and genetic terms. Thus, there may be some overlap among some categories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1166265\">",
"    <span class=\"h2\">",
"     Definition of benign versus malignant lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyoma variants are classified as benign or malignant based upon histologic features. Gross characteristics may suggest that a lesion is benign or malignant, but do not confirm a diagnosis. While some variants include lesions having extrauterine extension or dissemination, this does not automatically confer a diagnosis of malignancy if the histology is benign. On the other hand, some of the variants have histologic findings that make it difficult to define them as benign or malignant (eg, smooth muscle tumors of uncertain malignant potential). (See",
"    <a class=\"local\" href=\"#H23338835\">",
"     'Smooth muscle tumors of uncertain malignant potential'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Benign smooth muscle tumors (ie, leiomyomas of the usual histologic type or &ldquo;garden-variety&rdquo; leiomyomas) are defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low mitotic index (&lt;5 mitoses per 10 high power fields [HPF])",
"     </li>",
"     <li>",
"      No cytologic atypia",
"     </li>",
"     <li>",
"      No cell necrosis (apart from bland degeneration due to tumor ischemia)",
"     </li>",
"     <li>",
"      Spindle-shaped cells that are uniform in size and shape",
"     </li>",
"     <li>",
"      No intravascular component",
"     </li>",
"     <li>",
"      Well-circumscribed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smooth muscle tumors are designated as malignant according to three histologic characteristics, and the various combinations that define malignancy were proposed based upon the largest clinicopathological series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abundant mitoses (&ge;10 per 10 high power fields [HPF])",
"     </li>",
"     <li>",
"      Prominent cellular atypia",
"     </li>",
"     <li>",
"      Areas of coagulative tumor cell necrosis in a &ldquo;geographic&rdquo; (like islands on a map) fashion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338835\">",
"    <span class=\"h1\">",
"     SMOOTH MUSCLE TUMORS OF UNCERTAIN MALIGNANT POTENTIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine smooth muscle tumors of uncertain malignant potential (STUMP) have some characteristics of sarcomas, but do not meet full diagnostic criteria. (See",
"    <a class=\"local\" href=\"#H1166265\">",
"     'Definition of benign versus malignant lesions'",
"    </a>",
"    above.) These tumors are rare and thus, the paucity of data makes it difficult to describe their clinical behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16699004\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controversy exists regarding the classification of these tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. The focus of this debate is which of the criteria for malignant disease (high mitotic activity, cellular atypia, necrosis) should be used to most accurately identify the metastatic potential of a particular tumor. Other histologic parameters, such as the presence of atypical mitotic figures or tumor invasion into adjacent myometrium, may also be associated with malignant outcomes.",
"   </p>",
"   <p>",
"    A particular pattern of coagulative necrosis is the feature that best predicts malignant behavior according to the largest clinicopathologic series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/5\">",
"     5",
"    </a>",
"    ]. This pattern of necrosis has irregular, &ldquo;geographic&rdquo; shapes like islands on a map, and a sharp transition between viable and non-viable tumor tissue. More than one area of geographic tumor necrosis often is present. Geographic tumor necrosis must be distinguished from more common degenerative processes, usually due to ischemia or abrupt hormonal changes commonly found in benign leiomyomas.",
"   </p>",
"   <p>",
"    One area of ambiguity in the largest series centers on the four patients with tumors having coagulative necrosis without significant cellular atypia or a high mitotic index (&lt;10 mitoses per 10 HPF); one of these four patients had recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, these tumors were designated \"smooth muscle tumors of low malignant potential, limited experience.\" Another problematic area is when necrosis is identified, but cannot be unambiguously classified as being malignant-type geographic or benign-type ischemic necrosis. Because of the importance of classifying necrosis, such difficult tumors may be diagnosed as having an uncertain malignant potential.",
"   </p>",
"   <p>",
"    It remains to be determined whether STUMP represents a real phenotypic overlap between pathogenetically separate benign and malignant neoplasms. Alternatively, STUMP may represent a true intermediate in a pathway progressing from benign to malignant. Our experience, however, teaches us that smooth muscle tumors with features falling just short of satisfying the criteria defined by the largest series also may be malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/5\">",
"     5",
"    </a>",
"    ]. Consequently, atypical smooth muscle tumors with 8 or 9 mitoses per 10 HPF may be regarded as STUMP, particularly if they have other worrisome features such as atypical mitotic figures or destructive tumor cell infiltration into the smooth muscle fascicles of adjacent myometrium. Smooth muscle tumors with very high mitotic rates (&gt;15 per 10 HPF) also may merit the diagnosis of STUMP due to their rarity and unpredictability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16698997\">",
"    <span class=\"h2\">",
"     Clinical features and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of STUMP are the same as benign leiomyomas and uterine sarcomas, ie, uterine mass, abnormal uterine bleeding, and pelvic",
"    <span class=\"nowrap\">",
"     pain/pressure.",
"    </span>",
"    Likewise, there is no imaging modality that can reliably distinguish these lesions from other uterine tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H1430474#H1430474\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H1430514#H1430514\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    STUMP is diagnosed following myomectomy or hysterectomy. There are no available guidelines regarding whether hysterectomy, if not already performed, is required in women with this diagnosis. For women who have been diagnosed with STUMP following myomectomy, a detailed discussion should be held with the patient to review the characteristics of the tumor and the patient&rsquo;s plans for future pregnancy. Management options include hysterectomy or annual surveillance with pelvic imaging. More frequent surveillance may be warranted, especially in the first several years and depending upon the histologic features of the tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    factors may interfere with the pathology evaluation (eg, the tumor was incompletely excised or was morcellated at the time of surgery). If pelvic imaging is used, we used transvaginal ultrasound to rule out the presence of new uterine masses and magnetic resonance imaging with gadolinium to evaluate new uterine masses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167790\">",
"    <span class=\"h1\">",
"     BENIGN HISTOLOGIC VARIANTS OF LEIOMYOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign histologic variants of leiomyomas exhibit the same",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    as ordinary leiomyomas. There are no imaging modalities that can distinguish histologic variants from other leiomyomas. They are diagnosed by pathology examination following myomectomy or hysterectomy. Management is the same as for ordinary leiomyomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1166554\">",
"    <span class=\"h2\">",
"     Atypical leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The current World Health Organization (Stanford) schema uses the term atypical leiomyoma; older synonymous names include pleomorphic, symplastic, and bizarre leiomyoma.",
"   </p>",
"   <p>",
"    This histologically defined tumor has focal, multifocal or diffuse atypia (",
"    <a class=\"graphic graphic_picture graphicRef78545 \" href=\"UTD.htm?4/50/4901\">",
"     picture 1",
"    </a>",
"    ). The presence or absence of atypia is usually judged based upon nuclear changes, but cytoplasmic changes may also be evident. In addition to hyperchromasia, nuclear enlargement and pleomorphism, giant tumor cells with multiple and multilobated nuclei are common. The atypia must be &ldquo;significant&rdquo; (moderate to severe in histologic terms); tumors with mild changes are not classified as atypical leiomyomas. Other histologic features of malignancy, particularly coagulative necrosis and increased proliferative rates (&gt;10 mitoses per 10 HPF), cannot be present. Identification of other non-canonical findings such as atypical mitotic figures or infiltrative tumor margins in an atypical uterine smooth muscle tumor may prompt diagnostic consideration of leiomyosarcoma or STUMP.",
"   </p>",
"   <p>",
"    These lesions generally have a high cure rate with surgery alone (only 1 of 46 patients had metastatic or recurrent disease in the Stanford series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/5\">",
"     5",
"    </a>",
"    ]), and consequently have been regarded as a variant of benign leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare exceptions to this may exist; a small case series reported that 3 of 18 women with cellular or atypical variants died of their disease; of note, there was a longer latency between diagnosis and death in these patients compared with those with leiomyosarcoma (&gt;6 years versus median of 2.1 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/9\">",
"     9",
"    </a>",
"    ]. In our practice, we have seen several cases of tumors classified as an atypical leiomyoma develop into leiomyosarcoma in as few as four years. In addition, an atypical leiomyoma with deletions of 1p have expression profiles more similar to leiomyosarcoma than typical leiomyoma and myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/10\">",
"     10",
"    </a>",
"    ]. Observations such as these are the foundation for the hypothesis that some atypical leiomyomas represent intermediate forms with the capacity to evolve into recognizable leiomyosarcomas.",
"   </p>",
"   <p>",
"    Management is the same as for women with smooth muscle tumors of uncertain malignant potential. (See",
"    <a class=\"local\" href=\"#H16698997\">",
"     'Clinical features and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16698972\">",
"    <span class=\"h2\">",
"     Mitotically active leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to the other histologic variants of leiomyomas, this variant is defined by the isolated presence of one feature associated with malignancy, namely increased proliferative activity. Specifically, a leiomyoma with an increased mitotic count (&gt;5 but fewer than 15 mitoses per 10 HPF) but lacking atypia or geographic tumor necrosis merits classification as a mitotically active leiomyoma.",
"   </p>",
"   <p>",
"    These leiomyomas are typically small, well circumscribed, and almost always behave in a benign fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ]. Mitotically active leiomyomas are often hypercellular, and cellular leiomyoma are often mitotically active. Interestingly, the hormonal milieu appears to influence mitotic index. Leiomyomas are more likely to have a high mitotic count if they are excised during the secretory phase of the menstrual cycle, during pregnancy, or when women are receiving exogenous progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smooth muscle tumors with exceedingly high mitotic counts (&gt;15 per 10 HPF) are rare, and some have been associated with malignant outcomes. Consequently, the diagnosis of STUMP is appropriate for extremely proliferative tumors, even in the absence of other histologic features of malignancy.",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of these leiomyomas are the same as for ordinary leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23364268\">",
"    <span class=\"h2\">",
"     Cellular leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular leiomyomas are defined as having significantly more cellularity than the surrounding myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. Cellular leiomyomas often come to attention because an unusual gross appearance is appreciated; their cut surfaces are generally more tan, and less firm or rubbery than typical leiomyomas. Although cellular leiomyomas have typically been considered a benign histologic variant, some evidence suggests that this phenotype, when distinguished by the loss of chromosome 1p, has a gene profile more similar to leiomyosarcomas than leiomyomas or normal myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/10\">",
"     10",
"    </a>",
"    ]. Additionally, in two small clinical series, in which karyotype analysis was not available, cellular leiomyomas were associated with aggressive clinical behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/9,14\">",
"     9,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In histologic terms, this type of leiomyoma variant must have markedly greater cellularity than usual, and some have suggested that no more than 5 percent of all fibroids should be classified as being a cellular variant. One practical definition is to apply this diagnosis only to smooth muscle tumors with hypercellularity resembling endometrial stromal sarcoma (ESS). In fact, care must be taken not to misclassify ESS as cellular leiomyoma. One histologic feature of cellular leiomyoma is the presence of thick-walled blood vessels, whereas ESS has vessels resembling the spiral arterioles of proliferative endometrium. Correct distinction between a cellular leiomyoma and ESS may require tumor phenotyping by immunohistochemistry. Cellular leiomyoma, like other smooth muscle tumors, express smooth muscle actin, desmin, and h-caldesmon. In contrast, ESS usually does not express these markers of smooth muscle differentiation, but generally expresses CD10 more strongly, diffusely, and frequently than cellular leiomyoma and other smooth muscle tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=see_link&amp;anchor=H6#H6\">",
"     \"Uterine sarcoma: Classification, clinical manifestations, and diagnosis\", section on 'Endometrial stromal sarcomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management is the same as for women with smooth muscle tumors of uncertain malignant potential. (See",
"    <a class=\"local\" href=\"#H16698997\">",
"     'Clinical features and management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167813\">",
"    <span class=\"h2\">",
"     Myxoid leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxoid leiomyomas contain abundant extracellular stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. Myxoid change can be a focal finding in up to 12 percent of ordinary leiomyomas. These lesions appear to have no premalignant potential; however, myxoid leiomyoma must be distinguished from their malignant counterpart. Careful examination for the presence of nuclear atypia or myometrial infiltration is needed to exclude myxoid leiomyosarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167935\">",
"    <span class=\"h2\">",
"     Epithelioid leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelioid leiomyomas are benign tumors in which rounded or polygonal cells that appear similar to epithelial cells make up at least 50 percent of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. Previous terms for this entity were leiomyoblastomas or clear cell leiomyomas. True epithelioid leiomyomas are very rare. Based upon a more limited experience compared to the other variants, malignant potential may be associated with far lower mitotic rates (&gt;5 per 10 HPF) in epithelioid smooth muscle tumors with atypia.",
"   </p>",
"   <p>",
"    In addition, the diagnosis of a neoplasm with perivascular epithelioid cell differentiation (PEComa) should be considered in the differential diagnosis of any epithelioid smooth muscle tumor. PEComas are typically comprised of epithelioid cells with clear cytoplasm and express markers of melanocytic differentiation such as HMB-45, melan A (aka Mart 1), and MitF in addition to smooth muscle markers. (See",
"    <a class=\"local\" href=\"#H23338849\">",
"     'Lymphangioleiomyomatosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1168074\">",
"    <span class=\"h3\">",
"     Plexiform leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plexiform leiomyomas are epithelioid tumors that appear histologically as nested or ribbon-like areas of smooth muscle cells surrounded by extensive extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. There are rare reports of plexiform tumors of the uterus having quasi-malignant behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/15\">",
"     15",
"    </a>",
"    ], and this histologic pattern is often found in intravenous leiomyomatosis. (See",
"    <a class=\"local\" href=\"#H1167278\">",
"     'Intravenous leiomyomatosis'",
"    </a>",
"    below.) Genetic analysis, however, suggests they are a benign variant in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1168177\">",
"    <span class=\"h2\">",
"     Dissecting leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dissecting leiomyoma (cotyledonoid leiomyoma) is characterized by a pattern of nodular smooth muscle tumorlets surrounded by a hydropic matrix that appears to permeate or penetrate into adjacent myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. These tumors may extend beyond the uterus and involve the broad ligament, resulting in pelvic congestion and an appearance similar to the placental cotyledons.",
"   </p>",
"   <p>",
"    The nodularity seen in this variant likely represents an extreme form of hydropic degeneration. Patches of watery degeneration, often associated with chronic ischemic changes, are common in garden-variety leiomyoma. Other extreme forms of hydropic degeneration include cystification or cavitation.",
"   </p>",
"   <p>",
"    On gross examination, in addition to their architectural abnormalities, such degenerating tumors are often tan or brown, and softer than typical leiomyomas, as they have less collagenous material in their extracellular matrices. Microscopic examination of such tumors reveals the bland histologic features shared with typical leiomyoma.",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of these leiomyomas are the same as for ordinary leiomyomas. An exception to this is that hysterectomy is more likely to be technically feasible in women with this type of disease than myomectomy because of the larger size of the lesions and the often poorly defined gross margins with the adjacent myometrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167264\">",
"    <span class=\"h1\">",
"     BENIGN UTERINE VARIANTS WITH EXTRAUTERINE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several leiomyoma variants that are characterized by histologic features essentially identical to benign uterine leiomyomas, but with quasi-malignant dissemination to the pelvic veins and vena cava, peritoneal cavity, or other distant sites, such as the lungs. These conditions occur primarily in reproductive age women and often respond to therapies that reduce serum estrogen concentration. &nbsp;The pathobiological mechanism(s) accounting for their paradoxical features remains to be determined.",
"   </p>",
"   <p>",
"    The differential diagnosis of these conditions is broad, including malignant and infectious processes that result in intraabdominal, intravascular, or lung nodules; however, their striking histologic resemblance to uterine fibroids should lead to the correct diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16699283\">",
"    <span class=\"h2\">",
"     Leiomyomatosis peritonealis disseminata",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomatosis peritonealis disseminata (LPD) or disseminated peritoneal leiomyomatosis is a rare clinical entity in which multiple nodules stud the pelvic and peritoneal surfaces, often giving the appearance of metastatic ovarian or peritoneal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/17\">",
"     17",
"    </a>",
"    ]. Although this disorder is generally benign, a small number (probably &lt;5 percent) of LPD cases appear to undergo malignant transformation.",
"   </p>",
"   <p>",
"    Molecular studies suggest that LPD is a uniclonal, metastatic process, yet it has cytogenetic findings more similar to ordinary leiomyoma than leiomyosarcoma. Reports of clusters of disease within families suggest a hereditary component [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. LPD also has been reported in some women who do not have uterine leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fewer than 200 cases of LPD have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20\">",
"     20",
"    </a>",
"    ]. The disease is primarily found in reproductive age women, although it has been described in postmenopausal women and in a few men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/19\">",
"     19",
"    </a>",
"    ]. Most patients are asymptomatic, and disease is usually discovered incidentally at time of abdominal surgery. Symptoms, if present, may include abdominal mass or distension. Diagnosis of LPD is based upon histologic analysis of the nodules.",
"   </p>",
"   <p>",
"    Asymptomatic disease does not require treatment. There appears to be a waxing and waning of this disease and many medications that lower estrogen have been reported to cause regression of the lesions for short periods of time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20\">",
"     20",
"    </a>",
"    ]. There have been reports of recurrence of this disease in women who have undergone oophorectomy, upon initiation of postmenopausal hormone therapy. The approach of surgical resection of nodules has been reported in cases of large nodules associated with symptoms. Hysterectomy is not indicated unless uterine symptoms are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1167278\">",
"    <span class=\"h2\">",
"     Intravenous leiomyomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous leiomyomatosis (IVL) is characterized by histologically benign smooth muscle lesions extending in a worm-like fashion into the uterine and pelvic veins, vena cava, and sometimes as far as the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/21\">",
"     21",
"    </a>",
"    ]. Origin from uterine leiomyomata can be documented by pathological examination in some cases, but a uterine origin cannot be confirmed for all cases, raising the possibility that a subset of lesions develop de novo from vascular smooth muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20\">",
"     20",
"    </a>",
"    ]. IVL macroscopically and microscopically resembles uterine fibroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. Although any of the histologic variants of leiomyoma may be seen in IVL, the plexiform histologic pattern is common. (See",
"    <a class=\"local\" href=\"#H1168074\">",
"     'Plexiform leiomyomas'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Fewer than 150 cases of IVL have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/22\">",
"     22",
"    </a>",
"    ]. IVL is found primarily in women of reproductive age, although some cases have been described in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13,20\">",
"     13,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with IVL may present with pelvic, abdominal, or cardiac symptoms, depending upon the degree of extension of the mass. Pelvic or abdominal symptoms include pain, abnormal uterine bleeding, and abdominal distension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20\">",
"     20",
"    </a>",
"    ]. A minority of patients present with significant dyspnea, an intracardiac mass, or evidence of right ventricular dysfunction (congestive heart failure, dyspnea, and syncope) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13,23\">",
"     13,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IVL is diagnosed based upon pelvic imaging with computed tomography or MRI that shows a leiomyomatous uterus with projections into the vasculature (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66678 \" href=\"UTD.htm?23/29/24018\">",
"     image 1",
"    </a>",
"    ); intracardiac evaluation is performed with cardiac echography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. Alternatively, the diagnosis is made following hysterectomy, when pathologic analysis reveals venous invasion and extension beyond the tumor mass from which IVL originates. The diagnosis can be further confirmed by cytogenetic evaluation of the involved tissue. The karyotypic changes are similar to those found in ordinary leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, IVL includes intravascular endometrial tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"     13",
"    </a>",
"    ]. In such cases, the differential diagnosis includes ESS. Features that differentiate IVL from ESS are: a lack of endometrial involvement, lack of myometrial invasion, predominance of smooth muscle over endometrial stroma, a low mitotic index, and a lack of cytologic atypia. In addition to IVL and ESS, other abdominopelvic tumors noted for worm-like intravenous and intracaval extension include uterine leiomyosarcoma and renal cell carcinoma. Immunohistochemical phenotyping of the tumor with markers of smooth muscle (smooth muscle actin, desmin, h-caldesmon), endometrial stromal (CD10), and epithelial (cytokeratins) differentiation is often helpful.",
"   </p>",
"   <p>",
"    Treatment with surgical resection of the intravascular mass is required in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Because our current understanding of pathogenesis suggests contiguous spread from the uterus to the vascular tree, hysterectomy appears to be indicated at the time of surgical intervention. There are also reports of improvement in symptoms with use of medications that decrease estrogen levels (eg, GnRH agonists, aromatase inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Tumor recurrence has been reported from 7 months to 15 years after hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Thus, posttreatment surveillance with abdominal or thoracic imaging is prudent. Accumulating evidence also suggests that IVL lesions may detach and travel hematogenously to the lung, where a benign metastasizing leiomyoma may form. This is another indication for serial chest imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9293634\">",
"    <span class=\"h2\">",
"     Benign metastasizing leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign metastasizing leiomyomas (BML) is a rare condition in which solitary leiomyoma-like nodules are present in a distant location, most commonly the lungs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54918 \" href=\"UTD.htm?23/53/24401\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/34\">",
"     34",
"    </a>",
"    ]. As BML occurs predominantly in women of reproductive age or older, the origin of BML is presumed to be the uterus. It is uncertain whether the lesions disseminate through vascular or lymphatic spread or proliferate from local smooth muscle tissue, although we favor a mechanism based on venous passage to the lung (ie, via venous embolism) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20,35\">",
"     20,35",
"    </a>",
"    ]. Many of the reported cases were in women with a history of pelvic surgery, which has raised the question of iatrogenic spread; however, there are also cases in which the uterine tumors were discovered simultaneously with or after the distant lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/36\">",
"     36",
"    </a>",
"    ]. Instances of BML following IVL also occur.",
"   </p>",
"   <p>",
"    BML has a low mitotic index (&lt;5 mitoses per 10 high power fields), lack of nuclear pleomorphism, and lack of local invasion consistent with benign disease; the course is indolent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20,35\">",
"     20,35",
"    </a>",
"    ]. Molecular studies suggest that this is a monoclonal process, similar to ordinary leiomyomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Approximately 150 case reports of BML have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/35\">",
"     35",
"    </a>",
"    ]. BML is found primarily in women of reproductive age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease is usually asymptomatic and is often discovered incidentally on a chest radiograph. Some patients present with chest pain, dyspnea, or cough. The diagnosis of BML is based upon histologic diagnosis of the extrauterine lesions with microscopic features of leiomyoma. BML must be distinguished from lymphangioleiomyomatosis, which presents with histologically similar lung lesions. Lymphangioleiomyomatosis, however, is characterized by destruction of the pulmonary interstitium by smaller, less circumscribed and more numerous smooth muscle proliferations. Most cases of BML appear to follow a prior uterine surgery for uterine leiomyomas and clinical pathologic analysis suggests that the lung lesions are clonally derived from the benign uterine lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/37\">",
"     37",
"    </a>",
"    ]. While hysterectomy may not be required to treat extrauterine disease, in the presence of uterine masses, a hysterectomy can rule out presence of a low grade uterine sarcoma. (See",
"    <a class=\"local\" href=\"#H23338849\">",
"     'Lymphangioleiomyomatosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Expectant management is an option for asymptomatic disease. Estrogen and progesterone receptors are present in BML lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/36\">",
"     36",
"    </a>",
"    ]. Treatment with oophorectomy, agents that decrease estrogen (eg, gonadotropin releasing hormone [GnRH] agonists, selective estrogen receptor modulators with antagonistic activity in the uterus, aromatase inhibitors), or progestins has resulted in tumor regression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23363872\">",
"    <span class=\"h1\">",
"     MULTIORGAN OR EXTRAUTERINE VARIANTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23338849\">",
"    <span class=\"h2\">",
"     Lymphangioleiomyomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphangioleiomyomatosis (LAM) is characterized by disorderly proliferation of histologically bland smooth muscle and small vascular spaces in the lung, where it results in cystification and airway obstruction. Although LAM is not thought to be associated with uterine leiomyoma, the cell of origin remains to be determined. It is associated with renal angiomyolipoma in 50 percent of sporadic cases and 70 percent of individuals with tuberous sclerosis complex (TSC) will develop LAM.",
"   </p>",
"   <p>",
"    LAM, however, is important to the differential diagnosis of leiomyoma variants for several reasons. First, LAM must be distinguished from benign metastasizing leiomyomas. Both diseases may present with lung lesions that have a similar appearance on imaging studies. By pathology examination, BML features a well circumscribed border with adjacent lung tissue, but LAM lesions diffusely infiltrate interstitial spaces in a manner that compromises lung function. Thus, BML requires only excision, but LAM ultimately may require lung transplantation. Second, both BML and LAM typically present in females of reproductive age. Third, LAM and uterine fibroids potentially may have overlapping pathogenetic mechanism(s). Dysregulation of the transcription factor HMGA2 has been reported in both diseases. In addition, in one animal model for uterine leiomyomas, the Eker rat, the leiomyomas are due to a spontaneous tuberous sclerosis gene (",
"    <em>",
"     TSC2",
"    </em>",
"    ) mutation; germline mutation of one",
"    <em>",
"     TSC2",
"    </em>",
"    allele and loss of heterozygosity of the other",
"    <em>",
"     TSC2",
"    </em>",
"    allele result in LAM in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Studies suggest that the mTOR pathway activation following TSC gene inactivation may produce a novel therapeutic target amenable to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAM is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4586?source=see_link\">",
"     \"Pulmonary lymphangioleiomyomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23364055\">",
"    <span class=\"h2\">",
"     Hereditary leiomyomatosis and renal cell carcinoma syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is a rare autosomal dominant syndrome in which affected family members have cutaneous and uterine leiomyomas and an aggressive form of papillary renal cell cancer. The cutaneous leiomyomas arise from the smooth muscle cells of the arrector pili in the hair follicle. The mutated gene fumarate hydratase, or fumarase (",
"    <em>",
"     FH",
"    </em>",
"    ), an enzyme in the Kreb&rsquo;s cycle. The mechanism by which",
"    <em>",
"     FH",
"    </em>",
"    acts as a tumor suppressor is not fully understood, but other Kreb&rsquo;s cycle genes are known to act as tumor suppressor genes for other tumor types (eg, familial paragangliomas and succinate dehydrogenase). Currently, the best mechanistic hypothesis posits that activation of hypoxia-induced metabolic pathways is involved in development of neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with HLRCC do not necessarily exhibit all its manifestations. Historically, the literature described Reed&rsquo;s syndrome or multiple cutaneous and uterine leiomyomas (MCUL1; OMIM #150800) as different diseases, which lack a malignant component [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Because fumarate hydratase was identified as the gene responsible for both MCUL1 and HLRCC, they are now considered to be the same disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Molecular studies have demonstrated that many different germline mutations are associated with these syndromes, but they all result in absent or truncated proteins or changes in highly conserved amino acids. The second (normal) allele typically is deleted in neoplastic cells (ie, somatic loss of heterozygosity), confirming the role of fumarate hydratase as a tumor suppressor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Individuals homozygous for fumarate hydratase mutations in their germline have a profound constitutional fumarate hydratase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Thus, the genotype-phenotype relationships for fumarate hydratase are an example of phenotypic heterogeneity.",
"   </p>",
"   <p>",
"    In cohorts outside of the United States, there appears to be an increased risk of uterine sarcomas, especially in premenopausal women who are traditionally not at high risk of sarcoma; however, this has not been demonstrated in a North American cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. One potential explanation for this geographical difference is that, given the traditionally high rate of hysterectomy in the US, at-risk women may have had their uterus removed prior to the development of disease. Uterine sarcomas associated with HLRCC syndrome are often found in premenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/50\">",
"     50",
"    </a>",
"    ]. Interestingly, the original report of Reed&rsquo;s syndrome described a young woman with a uterine sarcoma and a kidney lesion that had invaded the uterus, but it did not link malignancy to the syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/44\">",
"     44",
"    </a>",
"    ]. The cutaneous lesions are the key to identifying this rare variant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <em>",
"     FH",
"    </em>",
"    mutation is not thought to play a critical role in non-syndromic uterine leiomyoma initiation or growth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary kidney cancer syndromes\", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23364224\">",
"    <span class=\"h2\">",
"     Cowden syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Cowden syndrome (also known as Cowden disease or multiple hamartoma syndrome), uterine leiomyomas occur with other benign mesenchymal tumors (eg, lipomas) and mucocutaneous lesions due to a germline mutation of the",
"    <em>",
"     PTEN",
"    </em>",
"    tumor suppressor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/53\">",
"     53",
"    </a>",
"    ]. There are few data about this rare condition, but a literature review reported that uterine leiomyomas are found in 40 percent of women with this syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/54\">",
"     54",
"    </a>",
"    ]. Women with Cowden syndrome also have an increased risk of breast, endometrial, thyroid, kidney and colorectal cancers.",
"    <em>",
"     PTEN",
"    </em>",
"    mutation is not thought to play a pivotal role in sporadic uterine leiomyoma tumor biology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462459902#H462459902\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Cowden syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H21#H21\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Cowden syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H2#H2\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12062357\">",
"    <span class=\"h2\">",
"     Vulvar and esophageal leiomyomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;On chromosome Xq22.3, genes for the &alpha;5 and &alpha;6 monomers of non-fibrillar, basement membrane (type IV) collagen (",
"    <em>",
"     COL4A5",
"    </em>",
"    and",
"    <em>",
"     COL4A6",
"    </em>",
"    ) are arranged in a head-to-head fashion and share a common promoter region. The X-linked form of Alport syndrome, defined by nephropathy, deafness, and sometimes ocular anomalies, results when",
"    <em>",
"     COL4A5",
"    </em>",
"    is mutated in germline DNA. Diffuse leiomyomatosis, typically manifesting as esophageal, tracheobronchial, or vulvar lesions, with Alport syndrome is due to germline deletion of both",
"    <em>",
"     COL4A5",
"    </em>",
"    and",
"    <em>",
"     COL4A6",
"    </em>",
"    , typifying the definition of a contiguous gene syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/55\">",
"     55",
"    </a>",
"    ]. Pathogenetic, submicroscopic deletions of the overlapping promoters and adjacent 5&rsquo; regions may be as small as 13.4-kb [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/56\">",
"     56",
"    </a>",
"    ]. Interestingly, the mRNA of",
"    <em>",
"     COL4A6",
"    </em>",
"    is increased about 2-fold in non-syndromic (ie, typical &ldquo;garden variety&rdquo;) uterine leiomyoma, but decreased nearly 14-fold in uterine leiomyosarcoma relative to myometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/3/17465/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20798640\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a number of variants of uterine leiomyomas in which the smooth muscle tumor manifests one histologic facet of malignancy, yet lacks all others. Other quasi-malignant variants may spread in a metastatic or angioinvasive manner, but be histologically and clinically benign. (See",
"      <a class=\"local\" href=\"#H20798632\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Variants of leiomyomas that are confined to the uterus have the same clinical manifestations as benign leiomyomas and uterine sarcomas, ie, uterine mass, abnormal uterine bleeding, and pelvic",
"      <span class=\"nowrap\">",
"       pain/pressure.",
"      </span>",
"      There is no imaging modality that can reliably distinguish these lesions from other uterine tumors. Conditions that involve extrauterine disease have symptoms consistent with those disease sites (eg, lung and vena caval lesions may result in dyspnea). Many of these conditions are responsive to antiestrogenic therapy. (See",
"      <a class=\"local\" href=\"#H23338835\">",
"       'Smooth muscle tumors of uncertain malignant potential'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1167790\">",
"       'Benign histologic variants of leiomyomas'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1167264\">",
"       'Benign uterine variants with extrauterine disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uterine smooth muscle tumors are designated as malignant according to three histologic characteristics: abundant mitoses (&ge;10 per 10 high power fields), prominent cellular atypia, and areas of coagulative tumor cell necrosis. (See",
"      <a class=\"local\" href=\"#H1166265\">",
"       'Definition of benign versus malignant lesions'",
"      </a>",
"      above.) While other features, such as myometrial invasion or atypical mitoses, though not part of the World Health Organization (Stanford) criteria, may herald malignant behavior.",
"     </li>",
"     <li>",
"      Uterine smooth muscle tumors of uncertain malignant potential (STUMP) have some characteristics of sarcomas, but do not meet full diagnostic criteria. STUMP is diagnosed following myomectomy or hysterectomy. There are no definitive guidelines regarding whether hysterectomy, if not already performed, is required in women with this diagnosis, but careful follow-up is required at a minimum. (See",
"      <a class=\"local\" href=\"#H23338835\">",
"       'Smooth muscle tumors of uncertain malignant potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign histologic variants of leiomyomas include atypical, cellular, epithelioid, myxoid, hydropic, and dissecting leiomyomas. They are diagnosed following myomectomy or hysterectomy. Although their management is generally the same as ordinary leiomyomas, surveillance with pelvic imaging may be required. (See",
"      <a class=\"local\" href=\"#H1167790\">",
"       'Benign histologic variants of leiomyomas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leiomyomatosis peritonealis disseminate (LPD) is a rare entity in which multiple benign nodules stud the pelvic and peritoneal surfaces. Most patients are asymptomatic, and disease is discovered incidentally at time of abdominal surgery. Although biologically it is a uniclonal, metastasizing smooth muscle proliferation, LPD does not exhibit aggressive clinical behavior. Consequently, therapy most often is directed at alleviating associated symptoms due to the bulk or location of smooth muscle lesions. (See",
"      <a class=\"local\" href=\"#H16699283\">",
"       'Leiomyomatosis peritonealis disseminata'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intravenous leiomyomatosis is characterized by benign leiomyoma-like lesions with extension into the pelvic veins, and sometimes as far as the heart. Women with this condition may present with pelvic, abdominal, or cardiac symptoms. (See",
"      <a class=\"local\" href=\"#H1167278\">",
"       'Intravenous leiomyomatosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign metastasizing leiomyomas is a rare condition in which leiomyoma-like nodules are present both in the uterus and in a distant location, most commonly the lungs. (See",
"      <a class=\"local\" href=\"#H9293634\">",
"       'Benign metastasizing leiomyomas'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/1\">",
"      Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/2\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/3\">",
"      Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     Quade, BJ, Robboy, SJ. Uterine smooth muscle tumors. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed, Robboy, SJ, Mutter, GL, Prat, J, et al. (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.474.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/5\">",
"      Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/6\">",
"      Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/7\">",
"      Solomon LA, Schimp VL, Ali-Fehmi R, et al. Clinical update of smooth muscle tumors of the uterus. J Minim Invasive Gynecol 2005; 12:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/8\">",
"      Evans HL, Chawla SP, Simpson C, Finn KP. Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988; 62:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/9\">",
"      Giuntoli RL 2nd, Gostout BS, DiMarco CS, et al. Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. J Reprod Med 2007; 52:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/10\">",
"      Christacos NC, Quade BJ, Dal Cin P, Morton CC. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/11\">",
"      Perrone T, Dehner LP. Prognostically favorable \"mitotically active\" smooth-muscle tumors of the uterus. A clinicopathologic study of ten cases. Am J Surg Pathol 1988; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/12\">",
"      O'Connor DM, Norris HJ. Mitotically active leiomyomas of the uterus. Hum Pathol 1990; 21:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/13\">",
"      Ip PP, Tse KY, Tam KF. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol 2010; 17:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/14\">",
"      Taran FA, Weaver AL, Gostout BS, Stewart EA. Understanding cellular leiomyomas: a case-control study. Am J Obstet Gynecol 2010; 203:109.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/15\">",
"      Seidman JD, Thomas RM. Multiple plexiform tumorlets of the uterus. Arch Pathol Lab Med 1993; 117:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/16\">",
"      Hodge JC, Quade BJ, Rubin MA, et al. Molecular and cytogenetic characterization of plexiform leiomyomata provide further evidence for genetic heterogeneity underlying uterine fibroids. Am J Pathol 2008; 172:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/17\">",
"      Hardman WJ 3rd, Majmudar B. Leiomyomatosis peritonealis disseminata: clinicopathologic analysis of five cases. South Med J 1996; 89:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/18\">",
"      Quade BJ, McLachlin CM, Soto-Wright V, et al. Disseminated peritoneal leiomyomatosis. Clonality analysis by X chromosome inactivation and cytogenetics of a clinically benign smooth muscle proliferation. Am J Pathol 1997; 150:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/19\">",
"      Halama N, Grauling-Halama SA, Daboul I. Familial clustering of Leiomyomatosis peritonealis disseminata: an unknown genetic syndrome? BMC Gastroenterol 2005; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/20\">",
"      Vaquero ME, Magrina JF, Leslie KO. Uterine smooth-muscle tumors with unusual growth patterns. J Minim Invasive Gynecol 2009; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/21\">",
"      Worley MJ Jr, Aelion A, Caputo TA, et al. Intravenous leiomyomatosis with intracardiac extension: a single-institution experience. Am J Obstet Gynecol 2009; 201:574.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/22\">",
"      Fasih N, Prasad Shanbhogue AK, Macdonald DB, et al. Leiomyomas beyond the uterus: unusual locations, rare manifestations. Radiographics 2008; 28:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/23\">",
"      Andrade LA, Torresan RZ, Sales JF Jr, et al. Intravenous leiomyomatosis of the uterus. A report of three cases. Pathol Oncol Res 1998; 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/24\">",
"      Sun C, Wang XM, Liu C, et al. Intravenous leiomyomatosis: diagnosis and follow-up with multislice computed tomography. Am J Surg 2010; 200:e41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/25\">",
"      Quade BJ, Dal Cin P, Neskey DM, et al. Intravenous leiomyomatosis: molecular and cytogenetic analysis of a case. Mod Pathol 2002; 15:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/26\">",
"      Dal Cin P, Quade BJ, Neskey DM, et al. Intravenous leiomyomatosis is characterized by a der(14)t(12;14)(q15;q24). Genes Chromosomes Cancer 2003; 36:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/27\">",
"      Castelli P, Caronno R, Piffaretti G, Tozzi M. Intravenous uterine leiomyomatosis with right heart extension: successful two-stage surgical removal. Ann Vasc Surg 2006; 20:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/28\">",
"      Garc&iacute;a Rinaldi R, P&eacute;rez Hern&aacute;ndez J, Corbal&aacute; AR, et al. Surgical treatment of multiple intracardiac and pulmonary artery tumor implants embolic from uterine intravascular leiomyomatosis. Bol Asoc Med P R 2007; 99:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/29\">",
"      Wang J, Yang J, Huang H, et al. Management of intravenous leiomyomatosis with intracaval and intracardiac extension. Obstet Gynecol 2012; 120:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/30\">",
"      Bodner-Adler B, Bartl M, Wagner G. Intravenous leiomyomatosis of the uterus with pulmonary metastases or a case with benign metastasizing leiomyoma? Anticancer Res 2009; 29:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/31\">",
"      Biri A, Korucuoglu U, Zumrutbas N, et al. Intravenous leiomyomatosis treated with aromatase inhibitor therapy. Int J Gynaecol Obstet 2008; 101:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/32\">",
"      Grella L, Arnold TE, Kvilekval KH, Giron F. Intravenous leiomyomatosis. J Vasc Surg 1994; 20:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/33\">",
"      Evans AT 3rd, Symmonds RE, Gaffey TA. Recurrent pelvic intravenous leiomyomatosis. Obstet Gynecol 1981; 57:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/34\">",
"      Jautzke G, M&uuml;ller-Ruchholtz E, Thalmann U. Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Pathol Res Pract 1996; 192:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/35\">",
"      Awonuga AO, Shavell VI, Imudia AN, et al. Pathogenesis of benign metastasizing leiomyoma: a review. Obstet Gynecol Surv 2010; 65:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/36\">",
"      Rivera JA, Christopoulos S, Small D, Trifiro M. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. J Clin Endocrinol Metab 2004; 89:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/37\">",
"      Patton KT, Cheng L, Papavero V, et al. Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol 2006; 19:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/38\">",
"      Motegi M, Takayanagi N, Sando Y, et al. [A case of so-called benign metastasizing leiomyoma responsive to progesterone]. Nihon Kyobu Shikkan Gakkai Zasshi 1993; 31:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/39\">",
"      D'Armiento J, Imai K, Schiltz J, et al. Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res 2007; 67:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/40\">",
"      Walker CL, Hunter D, Everitt JI. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 2003; 38:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/41\">",
"      Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/42\">",
"      Pollard P, Wortham N, Barclay E, et al. Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome. J Pathol 2005; 205:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/43\">",
"      Pollard PJ, Bri&egrave;re JJ, Alam NA, et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/44\">",
"      Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. Acta Derm Venereol 1973; 53:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/45\">",
"      Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43. Am J Hum Genet 2001; 68:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/46\">",
"      Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/47\">",
"      Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/48\">",
"      Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003; 12:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/49\">",
"      Bayley JP, Launonen V, Tomlinson IP. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 2008; 9:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/50\">",
"      Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001; 98:3387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/51\">",
"      Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/52\">",
"      Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet 2006; 43:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/53\">",
"      Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet 2011; 48:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/54\">",
"      Pilarski R. Cowden syndrome: a critical review of the clinical literature. J Genet Couns 2009; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/55\">",
"      Zhou J, Mochizuki T, Smeets H, et al. Deletion of the paired alpha 5(IV) and alpha 6(IV) collagen genes in inherited smooth muscle tumors. Science 1993; 261:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/56\">",
"      Segal Y, Peissel B, Renieri A, et al. LINE-1 elements at the sites of molecular rearrangements in Alport syndrome-diffuse leiomyomatosis. Am J Hum Genet 1999; 64:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/3/17465/abstract/57\">",
"      Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15676 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-AF412BCB0E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17465=[""].join("\n");
var outline_f17_3_17465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20798640\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20798632\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23338813\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1166265\">",
"      Definition of benign versus malignant lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23338835\">",
"      SMOOTH MUSCLE TUMORS OF UNCERTAIN MALIGNANT POTENTIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16699004\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16698997\">",
"      Clinical features and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167790\">",
"      BENIGN HISTOLOGIC VARIANTS OF LEIOMYOMAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1166554\">",
"      Atypical leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16698972\">",
"      Mitotically active leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23364268\">",
"      Cellular leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167813\">",
"      Myxoid leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167935\">",
"      Epithelioid leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1168074\">",
"      - Plexiform leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1168177\">",
"      Dissecting leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1167264\">",
"      BENIGN UTERINE VARIANTS WITH EXTRAUTERINE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16699283\">",
"      Leiomyomatosis peritonealis disseminata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1167278\">",
"      Intravenous leiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9293634\">",
"      Benign metastasizing leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23363872\">",
"      MULTIORGAN OR EXTRAUTERINE VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23338849\">",
"      Lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23364055\">",
"      Hereditary leiomyomatosis and renal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23364224\">",
"      Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12062357\">",
"      Vulvar and esophageal leiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20798640\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/15676\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15676|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/29/24018\" title=\"diagnostic image 1\">",
"      Intravenous leiomyomatosis MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/53/24401\" title=\"diagnostic image 2\">",
"      Benign metastasizing leiomyomas radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15676|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/50/4901\" title=\"picture 1\">",
"      Atypical leiomyoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=related_link\">",
"      Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/4/35910?source=related_link\">",
"      Hereditary kidney cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/30/4586?source=related_link\">",
"      Pulmonary lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2408?source=related_link\">",
"      Uterine sarcoma: Classification, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_3_17466="Apprehension relocation tests";
var content_f17_3_17466=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Anterior shoulder instability tests",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 647px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These tests work in combination and are most easily performed with the patient supine. Further details are found in the text.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17466=[""].join("\n");
var outline_f17_3_17466=null;
var title_f17_3_17467="Paraneoplastic GI motor dysfunction";
var content_f17_3_17467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paraneoplastic gastrointestinal motor dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cancer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Autoantibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast cancer",
"       </td>",
"       <td>",
"        PCA-1, ANNA-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hodgkin lymphoma",
"       </td>",
"       <td>",
"        PCA-Tr, N-type Ca++Ab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ovarian cancer",
"       </td>",
"       <td>",
"        PCA-1, N-type Ca++Ab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small cell lung cancer",
"       </td>",
"       <td>",
"        ANNA-1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCA-1: type 1 Purkinje cell cytoplasmic antibody, also called anti-Yo;",
"     <br>",
"      ANNA2: antineuronal nuclear antibody type 2, also called anti-Ri;",
"      <br>",
"       PCA-Tr: Purkinje cell cytoplasmic antibody type Tr;",
"       <br>",
"        N-type Ca++Ab: antineuronal calcium channel antibody of N-type specificity;",
"        <br>",
"         ANNA-1: antineuronal nuclear antibody type 1, also called anti-Hu.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001; 96:373.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17467=[""].join("\n");
var outline_f17_3_17467=null;
var title_f17_3_17468="Prognosis RMS by primary site";
var content_f17_3_17468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognosis of nonmetastatic rhabdomyosarcoma according to site of primary tumor from two different clinical trials",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Site of primary tumor",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Five year rates, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        MMT-89",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        IRSG-IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        OS",
"       </td>",
"       <td class=\"subtitle3\">",
"        EFS",
"       </td>",
"       <td class=\"subtitle3\">",
"        OS",
"       </td>",
"       <td class=\"subtitle3\">",
"        EFS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orbit",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        93",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary (not bladder or prostate)",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary (bladder or prostate)",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck (nonparameningeal)",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck (parameningeal) &lt;3 years of age",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck (parameningeal) &ge;3 years of age",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limbs",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EFS: event-free survival; IRSG-IV: Intergroup Rhabdomyosarcoma Study Group IV protocol; MMT-89: International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study-89; OS: overall survival.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: J Clin Oncol 2005; 23:2586.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17468=[""].join("\n");
var outline_f17_3_17468=null;
var title_f17_3_17469="Complications of Kawasaki disease";
var content_f17_3_17469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F56475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F56475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of Kawasaki disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Shock",
"       </td>",
"       <td>",
"        ~7 percent",
"       </td>",
"       <td>",
"        <p>",
"         Associated features:",
"        </p>",
"        <ul>",
"         <li>",
"          Consumptive coagulopathy and cardiac abnormalities including impaired left ventricular systolic function, mitral regurgitation, and coronary artery abnormalities",
"         </li>",
"         <li>",
"          Higher C-reactive protein levels",
"         </li>",
"         <li>",
"          Less responsive to initial intravenous immunoglobulin therapy and more commonly require additional treatment",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Macrophage activation syndrome",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Reported rarely in children with persistent fever after IVIG treatment",
"         </li>",
"         <li>",
"          Heralded by fall in ESR due to consumptive coagulopathy; also marked by ferritin levels &gt;5000 ng/mL",
"         </li>",
"         <li>",
"          Treatment with intravenous methylprednisolone, biologic response modifiers, or cyclosporine may be needed",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cardiac complications",
"       </td>",
"       <td>",
"        Coronary artery involvement",
"       </td>",
"       <td>",
"        <p>",
"         Nearly all patients with KD",
"        </p>",
"        <p>",
"         (Coronary artery ectasia - ~31 percent; coronary artery aneurysm -&nbsp;&lt;5 percent)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Coronary artery aneurysms associated with:",
"        </p>",
"        <ul>",
"         <li>",
"          Age &lt;1 year or &gt;9 years",
"         </li>",
"         <li>",
"          Male sex",
"         </li>",
"         <li>",
"          Fever &ge;14 days",
"         </li>",
"         <li>",
"          Serum sodium &lt;135 mEq/L, hematocrit &lt;35 percent, white cell count &gt;12,000/mm",
"          <sup>",
"           3",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depressed myocardial contractility",
"       </td>",
"       <td>",
"        Present in almost all patients with KD",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Includes myocarditis, cardiomyopathy, and left ventricular dysfunction",
"         </li>",
"         <li>",
"          Most commonly manifested by tachycardia and an S3 gallop; uncommonly may progress to heart failure",
"         </li>",
"         <li>",
"          Normal contractility typically is restored following treatment with intravenous immune globulin (IVIG)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Noncoronary vascular involvement",
"       </td>",
"       <td>",
"        <p>",
"         Rare (peripheral)",
"        </p>",
"        <p>",
"         Very rare (visceral)",
"        </p>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Peripheral aneurysms may present as pulsatile masses in axillae or inguinal area",
"         </li>",
"         <li>",
"          Peripheral arterial obstruction can lead to ischemia and gangrene",
"         </li>",
"         <li>",
"          Most commonly occurs in children with severe KD, including significant coronary artery involvement",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Urinary abnormalities and renal disease",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Includes acute interstitial nephritis, mild proteinuria, acute renal failure, hemolytic-uremic syndrome, and immune complex-mediated glomerulonephritis",
"         </li>",
"         <li>",
"          IVIG may also cause acute renal injury, especially preparations using sucrose as a stabilizer",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Gastrointestinal abnormalities",
"       </td>",
"       <td>",
"        Mild GI manifestations occur commonly; severe involvement is rare",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Mild GI involvement includes gallbladder hydrops and cholestasis and paralytic ileus",
"         </li>",
"         <li>",
"          More severe involvement includes bile duct stenosis, appendicular vasculitis, hemorrhagic duodenitis, intestinal pseudo-obstruction, intussusception, and pancreatitis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        Sensorineural hearing loss",
"       </td>",
"       <td>",
"        Rare",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Usually transient",
"         </li>",
"         <li>",
"          Persistent sensorineural hearing loss is associated with delayed use of IVIG, prolonged thrombocytosis, anemia, and an elevated erythrocyte sedimentation rate",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IVIG: intravenous immune globulin; ESR: erythrocyte sedimentation rate; KD: Kawasaki disease; GI: gastrointestinal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17469=[""].join("\n");
var outline_f17_3_17469=null;
var title_f17_3_17470="Effect of dynamic extrathoracic airway obstruction";
var content_f17_3_17470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of dynamic extrathoracic airway obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of forced expiration and inspiration in dynamic extrathoracic airway obstruction. Left panel, during forced expiration, intratracheal pressure (P",
"    <sub>",
"     tr",
"    </sub>",
"    ) exceeds the pressure around the airway (P",
"    <sub>",
"     atm",
"    </sub>",
"    ), lessening the obstruction. Right panel, during forced inspiration, when P",
"    <sub>",
"     tr",
"    </sub>",
"    falls below P",
"    <sub>",
"     atm",
"    </sub>",
"    , the obstruction worsens resulting in flow limitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Kryger M, Bode F, Antic R, et al. Am J Med 1976; 61:85.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17470=[""].join("\n");
var outline_f17_3_17470=null;
var title_f17_3_17471="Lumbosacral hemangioma";
var content_f17_3_17471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lumbosacral hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemangiomas located over the lumbosacral spine may be associated with spinal dysraphism or other underlying congenital anomalies. Segmental lesions, like the one depicted above, that span the midline and are flat or telangiectatic in appearance are of greatest concern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_3_17471=[""].join("\n");
var outline_f17_3_17471=null;
